{"gene":"MAPK1","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1991,"finding":"ERK2 (MAPK1) was cloned and identified as a protein-serine/threonine kinase activated by tyrosine phosphorylation in response to insulin and NGF, establishing it as an intermediate that converts tyrosine phosphorylation signals into serine/threonine phosphorylation cascades.","method":"Molecular cloning, biochemical kinase assays, phosphorylation analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — original cloning and biochemical characterization, foundational paper with 1747 citations","pmids":["2032290"],"is_preprint":false},{"year":1992,"finding":"ERK2 (42 kDa MAP kinase) is activated by phosphorylation on tyrosine and threonine downstream of oncogenic p21ras, and is constitutively activated in ras-transformed cell lines, placing ERK2 in the signal transduction pathway of the Ras oncoprotein.","method":"Scrape-loading of p21ras into cells, kinase activity assays, phosphorylation analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — epistasis/pathway placement with direct biochemical assays, highly cited foundational study","pmids":["1371463"],"is_preprint":false},{"year":1993,"finding":"cPLA2 is a direct substrate of MAP kinase (ERK); ERK phosphorylates cPLA2 at Ser-505, increasing its enzymatic activity, and mutation of Ser-505 to Ala abolishes agonist-stimulated arachidonate release.","method":"In vitro kinase assay, site-directed mutagenesis, arachidonate release assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis confirming functional site","pmids":["8381049"],"is_preprint":false},{"year":1993,"finding":"MAP kinase (ERK, p42/p44) phosphorylates the Elk-1 C-terminal region at multiple sites both in vitro and in vivo following growth factor stimulation, and this phosphorylation is required for transcriptional activation by the serum response element.","method":"In vitro phosphorylation, co-immunoprecipitation, transcriptional reporter assays, phosphopeptide mapping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay combined with functional mutagenesis and reporter assays, 1219 citations","pmids":["8386592"],"is_preprint":false},{"year":1993,"finding":"MKP-1 (3CH134) is a dual-specificity phosphatase that dephosphorylates p42MAPK (ERK2) at both T183 and Y185 in vitro and inactivates it in vivo; a catalytically inactive MKP-1 mutant forms a physical complex with phosphorylated ERK2.","method":"In vitro phosphatase assay, co-immunoprecipitation, dominant-negative mutant expression","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis, replicated in vivo, 1086 citations","pmids":["8221888"],"is_preprint":false},{"year":1997,"finding":"ERK MAP kinases phosphorylate Smad1 at specific serines in the linker region connecting its DNA-binding and effector domains, inhibiting nuclear accumulation of Smad1 and antagonizing BMP signaling.","method":"In vitro kinase assay, phosphopeptide mapping, nuclear localization assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation reconstitution with site identification, functional nuclear translocation assay","pmids":["9335504"],"is_preprint":false},{"year":1997,"finding":"Mnk1 and Mnk2 bind directly to ERK1/2 (with Mnk1 complexing more strongly with inactive than active ERK), and ERK phosphorylates Mnk1/2 to stimulate their kinase activity toward eIF-4E at Ser209.","method":"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site mapping","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — direct binding and in vitro phosphorylation assays with functional downstream readout","pmids":["9155017"],"is_preprint":false},{"year":1998,"finding":"MSK1 is directly activated by ERK2 (MAPK2/ERK2) in vitro, and endogenous MSK1 activation by growth factors is prevented by MEK inhibitor PD 98059; MSK1 phosphorylates CREB at Ser133, linking ERK2 signaling to CREB activation.","method":"In vitro kinase assay, pharmacological inhibition, CREB phosphorylation assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of direct ERK2→MSK1 phosphorylation with functional downstream CREB readout","pmids":["9687510"],"is_preprint":false},{"year":1998,"finding":"Phosphorylated ERK2 forms homodimers with both phosphorylated and unphosphorylated ERK2 partners; nuclear accumulation of ERK2 depends on its phosphorylation state and requires dimerization, as disruption of dimerization by mutagenesis reduces nuclear accumulation. Crystal structure of phosphorylated ERK2 reveals the structural basis for dimerization.","method":"Crystal structure determination, site-directed mutagenesis, microinjection, nuclear localization assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure combined with mutagenesis and functional nuclear translocation assay","pmids":["9604935"],"is_preprint":false},{"year":1999,"finding":"ERK2 residues 312–320 constitute a cytoplasmic retention sequence that mediates association with MEK1, retaining ERK2 in the cytosol; residues 316, 319, and 320 (acidic) are most critical. Residues 321–327 are required for nuclear translocation upon mitogenic stimulation.","method":"GFP-fusion protein expression, alanine-scanning mutagenesis, subcellular localization imaging","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct localization experiment with functional mutagenesis identifying specific residues","pmids":["10521408"],"is_preprint":false},{"year":1999,"finding":"ERK2 phosphorylates the transcription factor Sp1, and this phosphorylation stimulates Sp1 DNA binding; pretreatment with recombinant ERK2 increased Sp1 binding while dephosphorylation reduced it. Ras and ERK2 activation target the EGF-responsive gERE element via Sp1.","method":"In vitro phosphorylation assay, EMSA/DNA-binding assay, cotransfection reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct in vitro phosphorylation with functional DNA-binding readout; single lab","pmids":["9918860"],"is_preprint":false},{"year":1999,"finding":"Activated ERK2 directly associates with and phosphorylates the docking protein GAB1; this association is exclusive to phosphorylated ERK2 and does not require a third protein. In intact cells, GAB1 co-immunoprecipitates with active ERK2.","method":"Pull-down assay with purified proteins, co-immunoprecipitation, in vitro kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted direct interaction with purified proteins and in vitro phosphorylation, confirmed in cells","pmids":["10593929"],"is_preprint":false},{"year":1999,"finding":"ERK2 phosphorylates Smad2 and Smad3 at specific linker-region sites downstream of oncogenic Ras/ERK signaling, causing cytoplasmic retention and inhibiting TGF-β-induced nuclear accumulation and transcription. Ras-resistant Smad3 mutant rescues TGF-β growth inhibitory response.","method":"In vitro phosphorylation, site-directed mutagenesis, nuclear translocation assay, transcriptional reporter","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation, mutagenesis of specific sites, functional rescue, 843 citations","pmids":["10197981"],"is_preprint":false},{"year":1999,"finding":"RKIP (Raf kinase inhibitor protein) binds to Raf-1, MEK, and ERK in vitro and co-immunoprecipitates with Raf-1 and MEK from cells, competitively disrupting Raf-1/MEK interaction and suppressing ERK activation. RKIP overexpression inhibits MEK, ERK, and AP-1 activation.","method":"Yeast two-hybrid, co-immunoprecipitation, in vitro binding, kinase activity assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal binding and functional assays across labs, 723 citations","pmids":["10490027"],"is_preprint":false},{"year":2000,"finding":"MEKK1 binds directly to endogenous ERK2, MEK1, and Raf-1, suggesting it can scaffold all three components of the ERK2 MAP kinase module.","method":"Co-immunoprecipitation of endogenous proteins","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — co-immunoprecipitation of endogenous proteins, single lab","pmids":["10969079"],"is_preprint":false},{"year":2001,"finding":"Dual phosphorylation of ERK2 at Thr-185 and Tyr-187 increases overall catalytic efficiency ~600,000-fold and turnover rate ~50,000-fold, primarily through a ~60,000-fold enhancement of the phosphoryl group transfer step, with only modest decreases in Km for ATP and substrate.","method":"In vitro kinase assay, solvent viscosimetry, steady-state kinetics","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — detailed mechanistic in vitro kinetic analysis of catalytic mechanism","pmids":["11016942"],"is_preprint":false},{"year":2001,"finding":"ERK2 activation is required for glucose-stimulated insulin gene transcription; ERK2 phosphorylates transcription factors Beta2/NeuroD1 and PDX-1, increasing their functional activity and cumulatively transactivating the insulin promoter.","method":"Dominant-negative ERK2 expression, MEK inhibitors, in vitro phosphorylation, transcriptional reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — dominant-negative approach, pharmacological inhibition, and direct phosphorylation of substrates with functional readout","pmids":["12810726"],"is_preprint":false},{"year":2001,"finding":"ERK2 activation of the c-fos SRE through C/EBPbeta requires phosphorylation of a consensus MAPK site in C/EBPbeta; dominant-negative ERK2 (but not ERK1) blocks Ras-stimulated C/EBPbeta-SRF interaction, and recombinant ERK2 (but not ERK1) phosphorylates C/EBPbeta in vitro.","method":"Dominant-negative overexpression, in vitro kinase assay, co-immunoprecipitation, luciferase reporter","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro phosphorylation with isoform selectivity and functional reporter assay; single lab","pmids":["11500490"],"is_preprint":false},{"year":2001,"finding":"MUC1 cytoplasmic domain signaling leads to activation of ERK2 through the Ras-MEK-ERK2 pathway following tyrosine phosphorylation of MUC1; this was blocked by dominant-negative Ras or MEK inhibitor.","method":"Immunoblotting, kinase assay, immunocytochemistry, dominant-negative Ras, pharmacological inhibition","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 3 — functional assays with pharmacological/genetic inhibition, single lab","pmids":["11404250"],"is_preprint":false},{"year":2002,"finding":"Naf1α binds to ERK2 (confirmed by yeast two-hybrid, pull-down and co-immunoprecipitation); overexpression of Naf1α suppresses ERK2 nuclear translocation and inhibits ERK2-dependent Elk1-driven transcription, identifying Naf1α as an attenuator of activated ERK2 signaling.","method":"Yeast two-hybrid, pull-down assay, co-immunoprecipitation, nuclear translocation assay, luciferase reporter","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — multiple binding methods confirmed, functional consequence shown; single lab","pmids":["12220502"],"is_preprint":false},{"year":2003,"finding":"MKP3 dephosphorylates ERK2 via an intramolecular mechanism: a 1:1 MKP3:pERK monomer complex forms, and MKP3 within this complex performs intramolecular dephosphorylation, achieving ≥4000-fold rate enhancement through catalytic activation and substrate tethering.","method":"In vitro phosphatase assay, chemical cross-linking, binding analyses, engineered mutants","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and cross-linking, mechanistic characterization of stoichiometry","pmids":["14690430"],"is_preprint":false},{"year":2004,"finding":"IQGAP1 directly binds ERK2 (confirmed by in vitro pull-down with purified proteins and endogenous co-immunoprecipitation); manipulation of IQGAP1 levels significantly reduces growth factor-stimulated ERK1/2 activity, and an IQGAP1 construct lacking the ERK2-binding region does not interfere with ERK activation.","method":"In vitro pull-down with purified proteins, co-immunoprecipitation, siRNA knockdown, kinase activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct protein-protein interaction reconstituted in vitro, confirmed in cells with functional consequence","pmids":["14970219"],"is_preprint":false},{"year":2004,"finding":"ERK2 phosphorylates PAK1 at Thr212 in vitro, and Thr212 is phosphorylated in smooth muscle cells after PDGF treatment in an MEK/ERK-dependent manner. PAK1 and ERK1/2 directly associate (Far Western analysis) at an ERK2 binding site within PAK1's autoinhibitory domain, and this association facilitates ERK signaling. A phosphomimic PAK1-T212E variant attenuates downstream ERK signaling, providing negative feedback.","method":"In vitro kinase assay, Far Western, co-immunoprecipitation, immunolocalization, luciferase reporter","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding reconstituted, in vitro phosphorylation with site identification, functional consequence shown","pmids":["15542607"],"is_preprint":false},{"year":2004,"finding":"Nonapoptotic programmed cell death mediated by the NK1R/Substance P pathway is executed through a MAPK cascade (Raf-1, MEK2, ERK2) recruited by arrestin 2 as scaffold, leading to phosphorylation of the orphan nuclear receptor Nur77. RNAi against ERK2 (but not ERK1) blocks this cell death.","method":"RNAi knockdown, dominant-negative constructs, pharmacological inhibition, cell death assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific RNAi with defined phenotypic readout and pathway placement; single lab","pmids":["14769794"],"is_preprint":false},{"year":2004,"finding":"MEK1-ERK1/2 signaling is required for cardioprotection against ischemia-reperfusion injury; ERK2 heterozygous knockout mice show enhanced infarction, DNA laddering and TUNEL positivity, while MEK1 transgenic mice with activated ERK1/2 are resistant to injury.","method":"Gene-targeted knockout mice, transgenic overexpression, ischemia-reperfusion in vivo model, pressure-volume loop recordings, TUNEL assay","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function and gain-of-function in vivo with defined cardiac phenotype","pmids":["15096454"],"is_preprint":false},{"year":2004,"finding":"Noonan syndrome PTPN11/SHP2 mutants cause prolonged ERK2/MAPK1 activation in a ligand- and GAB1-docking-dependent manner; coexpression of GAB1-FF (lacking SHP2 binding motifs) blocks EGF-mediated increase in SHP2 phosphatase activity and reduces ERK2 activation.","method":"Kinase activity assays, co-immunoprecipitation, dominant-negative/mutant overexpression, proliferation assays","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 3 — functional pathway analysis with mutant proteins; single lab","pmids":["14974085"],"is_preprint":false},{"year":2005,"finding":"ERK2 uses a proximity-mediated catalysis mechanism: docking of a substrate recognition domain (pnt domain of EtsDelta138) outside the active site increases local concentration of the phosphoacceptor TP motif near the catalytic site; mutagenesis of the pnt domain reduces binding 10-fold but kcat is unchanged, while mutagenesis of the TP motif decreases kcat without affecting ternary complex stability.","method":"In vitro kinase assay, site-directed mutagenesis, binding studies","journal":"Journal of the American Chemical Society","confidence":"High","confidence_rationale":"Tier 1 — mechanistic reconstitution with systematic mutagenesis of both enzyme and substrate","pmids":["16045329"],"is_preprint":false},{"year":2005,"finding":"FR180204, an ERK-selective ATP-competitive inhibitor (Ki 0.14 µM for ERK2), binds within the ATP-binding pocket of ERK2 engaging residues Q105, D106, L156, and C166, as determined by X-ray crystallography of the human ERK2/FR180204 complex.","method":"X-ray crystallography, enzyme kinetic assay (Lineweaver-Burk), cell-based reporter assay","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with biochemical validation","pmids":["16139248"],"is_preprint":false},{"year":2005,"finding":"PEA-15 sequesters ERK2 in the cytoplasm by binding to ERK2 through a reverse DEJL domain in its C-terminus, thereby blocking ERK2 interactions with DEJL-containing substrates and inhibiting many ERK2-mediated phosphorylations.","method":"Fluorescence anisotropy binding assay, peptide displacement studies","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — quantitative binding data with mechanistic model; single lab","pmids":["16324895"],"is_preprint":false},{"year":2005,"finding":"ERK2 is required for cardioprotection, T cell development, positive selection, and CD4/CD8 T cell maturation; conditional and global knockout studies demonstrate ERK2's predominant in vivo roles compared to ERK1.","method":"Gene-targeted knockout mice, T cell development analysis, proliferation and survival assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function in vivo with defined cellular phenotypes at multiple developmental stages","pmids":["16226508"],"is_preprint":false},{"year":2005,"finding":"ERK MAP kinase phosphorylates TSC2 at specific Erk sites, causing dissociation of the TSC1-TSC2 complex and markedly impairing TSC2's ability to inhibit mTOR signaling and cell transformation; an Erk-nonphosphorylatable TSC2 mutant blocks tumorigenicity in vivo.","method":"In vitro phosphorylation, co-immunoprecipitation, mutagenesis, xenograft tumor model","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation with mutant rescue in vivo, 1067 citations","pmids":["15851026"],"is_preprint":false},{"year":2006,"finding":"ERK2 (but not ERK1, JNK, or p38) plays a specific role in cytosolic lipid droplet formation; ERK2 phosphorylates dynein, increasing its localization on ADRP-containing lipid droplets. ERK2 functions downstream of PLD1 in this process, without affecting PLD1 activity.","method":"siRNA knockdown, microinjection, overexpression, phosphorylation assay, lipid droplet quantification","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific knockdown and overexpression with mechanistic substrate identification; single lab","pmids":["16723731"],"is_preprint":false},{"year":2007,"finding":"Phosphorylated ERK2 directly interacts with and activates PARP-1 in a DNA-independent manner in a cell-free system; activated PARP-1 dramatically increases ERK2-catalyzed phosphorylation of Elk1. In cortical neurons and cardiomyocytes, PARP-1 activation enhances ERK-induced Elk1 phosphorylation, histone acetylation, and c-fos transcription.","method":"Cell-free reconstitution, co-immunoprecipitation, kinase assay, reporter gene assay, primary cell experiments","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — cell-free reconstitution of direct interaction with functional consequence, validated in primary cells","pmids":["17244536"],"is_preprint":false},{"year":2007,"finding":"ERK2 activation in platelets requires simultaneous signaling from both P2Y1 (Gq-coupled) and P2Y12 (Gi-coupled) ADP receptors plus Src kinase activity; ERK2 activation is required for ADP-induced thromboxane A2 generation, and extracellular calcium blocks ADP-induced ERK2 activation.","method":"Pharmacological inhibition of specific receptors/kinases, kinase activity assay, thromboxane measurement","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — defined pathway placement with multiple pharmacological tools and functional output; single lab","pmids":["17298299"],"is_preprint":false},{"year":2008,"finding":"Mitochondrially localized ERK2 activity is sufficient to induce mitophagy; active ERK2-CA shows greater localization to mitochondria than WT, and kinase activity (not just localization) correlates with degree of mitophagy. ERK2 localization to mitochondria is triggered by 6-OHDA.","method":"GFP-ERK2 fusion constructs (WT, CA, KD), colocalization imaging, autophagy marker analysis (LC3), bafilomycin treatment","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiments with kinase-dead controls establishing activity-dependent mitophagy; single lab","pmids":["18594198"],"is_preprint":false},{"year":2008,"finding":"ERK2 (but not ERK1) is required for proliferation of CD8 T cells activated without costimulation, and regulates CD8 T cell survival by transcriptionally upregulating Bcl-xL and downregulating Bim; impaired ERK2-deficient CD8 T cell survival can be rescued by genetic ablation of Bim.","method":"Conditional Erk2 knockout, viral infection model, in vitro activation, Bim genetic rescue","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with mechanistic rescue, isoform-specific role defined","pmids":["19017950"],"is_preprint":false},{"year":2008,"finding":"ERK2 morpholino knockdown in zebrafish blocks initiation of epiboly, actin/tubulin cytoskeleton reorganization, and causes severe anterior-posterior extension defects; ERK2 mRNA cross-rescues ERK1 morphants, but ERK1 mRNA cannot rescue ERK2 morphants, suggesting distinct functions.","method":"Morpholino knockdown, mRNA rescue, cell-tracing, cytoskeleton imaging in zebrafish embryos","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — morpholino knockdown with cross-rescue in vertebrate model organism; single lab","pmids":["18514184"],"is_preprint":false},{"year":2011,"finding":"Large-scale chemical-genetic screen using analog-sensitive ERK2 identified 80 ERK2 substrates; ETV3 is a novel substrate extensively phosphorylated at canonical and noncanonical ERK motifs, and this phosphorylation prevents ETV3 binding to DNA at promoters of thousands of genes including negative feedback regulators.","method":"Analog-sensitive kinase assay (chemical genetics), mass spectrometry, ChIP-seq, reporter assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 — systematic in vitro substrate identification with functional validation of novel substrate ETV3","pmids":["22028470"],"is_preprint":false},{"year":2011,"finding":"The ERK2:HePTP complex transitions from a highly extended dynamic resting-state conformation to a compact, ordered active-state conformation as determined by SAXS combined with EROS ensemble refinement; HePTP negatively regulates ERK2 via dephosphorylation.","method":"Small-angle X-ray scattering (SAXS), EROS ensemble refinement","journal":"Journal of the American Chemical Society","confidence":"Medium","confidence_rationale":"Tier 2 — solution structural determination with functional context; single lab","pmids":["21985012"],"is_preprint":false},{"year":2012,"finding":"ERK1/2-dependent phosphorylation of PKM2 at Ser37 (by ERK2 binding directly to PKM2 Ile429/Leu431 through the ERK2 docking groove) recruits PIN1 for cis-trans isomerization, promotes PKM2 nuclear translocation, and nuclear PKM2 acts as β-catenin coactivator to induce c-Myc and the Warburg effect.","method":"In vitro kinase assay, co-immunoprecipitation, mutagenesis, nuclear fractionation, xenograft tumor model","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 — direct ERK2-PKM2 interaction characterized at residue level, in vitro phosphorylation, in vivo functional consequence, 769 citations","pmids":["23178880"],"is_preprint":false},{"year":2013,"finding":"ERK2-mediated phosphorylation of RhoA is required for SCF(FBXL19)-mediated RhoA ubiquitination at Lys135 and proteasomal degradation; RhoA-K135R mutant is resistant to FBXL19-mediated ubiquitination. ERK2 phosphorylation of RhoA is both sufficient and required for this degradation.","method":"In vitro kinase assay, ubiquitination assay, mutagenesis, co-immunoprecipitation, protein stability assay","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation required for ubiquitination reconstituted, with mutagenesis confirmation","pmids":["23871831"],"is_preprint":false},{"year":2013,"finding":"PLAC8 directly binds and inactivates the ERK2 phosphatase DUSP6 in vitro, thereby increasing phospho-ERK2 levels and driving an unconventional EMT in colon cancer characterized by increased VIM, ZEB1, and CDH3 without CDH2 upregulation; ERK2 knockdown reverses these EMT features.","method":"In vitro protein binding assay, ERK2 knockdown, immunofluorescence, xenograft model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical interaction of PLAC8 with DUSP6 in vitro, ERK2 KD with functional rescue, confirmed in vivo","pmids":["24691442"],"is_preprint":false},{"year":2014,"finding":"Dual phosphorylation of ERK2 by MAP kinase kinase 1 induces global conformational exchange dynamics (two-state exchange, kex ≈ 300 s⁻¹) throughout the conserved kinase core, releasing constraints on domain motions; inactive ERK2 shows only localized, uncoupled side-chain dynamics.","method":"NMR 13C relaxation dispersion experiments (side-chain methyl dynamics), phosphorylation by MKK1","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — NMR structural dynamics with functional validation via phosphorylation-induced changes","pmids":["24550275"],"is_preprint":false},{"year":2014,"finding":"ERK2 directly phosphorylates NANOG at multiple sites in vitro; using the MAKS multiplexed kinase assay, ERK2 and CDK1/CyclinA2 were identified as site-specific kinases for human NANOG, linking key signaling pathways to pluripotency regulation.","method":"MAKS (multiplexed assay for kinase specificity), mass spectrometry phosphopeptide mapping","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro direct phosphorylation with site identification; single lab, no in vivo functional rescue","pmids":["24678451"],"is_preprint":false},{"year":2015,"finding":"ERK2 dimerization is essential for extranuclear (but not nuclear) ERK signaling; a small molecule inhibitor of ERK dimerization prevents RAS-ERK oncogene-driven tumorigenesis without affecting ERK phosphorylation, demonstrating that dimerization controls sub-localization-specific ERK signaling.","method":"Small molecule inhibitor design, dimerization assays, cancer cell transformation assays, mouse tumor models","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — pharmacological disruption of dimerization with in vivo functional consequence, mechanistic dissection of nuclear vs extranuclear signaling","pmids":["26267534"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of ERK2 in complex with RSK1 reveals a precatalytic kinase-kinase heterodimer where the RSK1 activation loop faces ERK2's catalytic site; the MAPK-binding linear motif in RSK1's disordered kinase domain extension docks into ERK2's groove to form the encounter complex, and generic kinase domain surface contacts enable the catalytically competent state.","method":"X-ray crystallography, molecular dynamics simulation, biochemical and cellular kinase assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with MD simulation and biochemical validation","pmids":["25730857"],"is_preprint":false},{"year":2015,"finding":"Under low-glucose metabolic stress, isoform-specific MEK1/ERK2 signaling (not ERK1) activates GCN2/eIF2α phosphorylation and ATF4 expression, which overrides PERK/Akt-mediated adaptation and induces apoptosis through ATF4-dependent pro-apoptotic factor expression including Bid and Trb3. ERK2 activation also alters TCA cycle and amino acid metabolism.","method":"Isoform-specific knockdown/overexpression, phosphoproteomics, metabolomics, apoptosis assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — isoform-specific manipulation with mechanistic pathway placement and metabolic readouts; multiple methods","pmids":["26190261"],"is_preprint":false},{"year":2017,"finding":"Akt, Erk2, and IKK1/2 phosphorylate Bcl3 at distinct sites: Erk2 and IKK1/2 phosphorylate Ser114 and Ser446, converting Bcl3 from an IκB-like inhibitor to a transcriptional coregulator by facilitating its recruitment to DNA. Cells expressing S114A/S446A Bcl3 have proliferation and migration defects.","method":"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, ChIP, cell proliferation and migration assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro direct phosphorylation with mutagenesis and functional consequences in cells","pmids":["28689659"],"is_preprint":false},{"year":2017,"finding":"In BRAF-inhibitor-resistant melanoma, ERK2 kinase drives a phenotype switch (resembling EMT with MITF shutdown) upon drug withdrawal, through a pathway involving ERK2, JUNB, and FRA1 transcription factors; CRISPR-Cas9 screen identified this as the core 'drug addiction' pathway.","method":"Unbiased CRISPR-Cas9 knockout screen, transcriptomics, mouse tumor models, patient sample analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genome-wide unbiased screen with in vivo validation and patient sample confirmation","pmids":["28976960"],"is_preprint":false},{"year":2019,"finding":"ERK inhibitors Vertex-11e and SCH772984 exploit conformational equilibrium in active 2P-ERK2 by shifting exchange between two states (L and R) in opposing directions; X-ray structures and NMR/HX-MS measurements show that the L→R shift in 2P-ERK2 involves active site domain closure for productive nucleotide binding, and these inhibitors differentially affect MAP kinase phosphatase activity toward 2P-ERK2.","method":"NMR, X-ray crystallography, hydrogen-exchange mass spectrometry, phosphatase activity assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structures combined with NMR and HX-MS and functional phosphatase assays","pmids":["31311868"],"is_preprint":false},{"year":2020,"finding":"MAPK1/ERK2-MAPK3/ERK1 kinase phosphorylates ULK1, triggering ULK1 interaction with BTRC and subsequent K48-linked ubiquitination and proteasomal degradation. ULK1 depletion attenuates mitophagy during hypoxia, causing accumulation of ROS-generating mitochondria and NLRP3 inflammasome activation that promotes breast cancer bone metastasis.","method":"Co-immunoprecipitation, in vitro kinase assay, ubiquitination assay, MEK inhibitor (trametinib), xenograft model","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — direct phosphorylation of ULK1 by ERK, ubiquitination mechanism defined, functional in vivo consequence","pmids":["33213267"],"is_preprint":false},{"year":2020,"finding":"Mechanical force (centrifugal, compression, stretching) rapidly activates Erk2 in Xenopus embryos in an FGFR1-dependent but FGF-ligand-independent manner; Erk2 activation induces cytoskeletal remodeling (F-actin, C-cadherin, ZO-1), enhancing cellular junctions and tissue stiffening during early embryogenesis.","method":"Phosphoproteome analysis of Xenopus embryos, force application experiments, FGFR1 inhibition, cytoskeletal protein analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — phosphoproteomics in intact embryo model with pharmacological intervention; single lab","pmids":["32187556"],"is_preprint":false},{"year":2023,"finding":"MAPK1 binds directly to promoter regions of target genes as a bidirectional transcription factor in gastric cancer cells; ChIP-seq and biochemical assays demonstrate MAPK1 upregulates KRT13, KRT6A, KRT81, MYH15, STARD4, SYTL4, TMEM267 and downregulates FGG, promoting cell invasion and migration.","method":"ChIP-seq, ChIP assay, RNA sequencing, protein interaction assays, cell migration/invasion assays","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq with functional cellular assays; single lab, novel transcription factor role","pmids":["37817112"],"is_preprint":false}],"current_model":"MAPK1/ERK2 is a dual-specificity-activated serine/threonine kinase that, upon dual phosphorylation at Thr185/Tyr187 by MEK1/2 (causing a ~600,000-fold increase in catalytic efficiency and global conformational exchange enabling active-site closure), dimerizes and translocates to the nucleus where it phosphorylates transcription factors (Elk-1, Sp1, C/EBPβ, ETV3, NANOG, Beta2/PDX-1), and in the cytoplasm phosphorylates diverse substrates (cPLA2, Smad1/2/3, TSC2, PKM2, RhoA, ULK1, PAK1, Bcl3, dynein) to regulate proliferation, survival, differentiation, motility, metabolism, autophagy/mitophagy, and gene expression; its activity is spatially controlled by scaffold proteins (β-arrestin, IQGAP1, MEKK1), cytoplasmic retention via MEK1 binding to residues 312–320, inhibitory binding partners (PEA-15, Naf1α), and inactivation by dual-specificity phosphatases (MKP-1, MKP3/DUSP6, HePTP), while ERK2 dimerization specifically governs extranuclear signaling and can also function as a direct transcription factor binding to gene promoters."},"narrative":{"teleology":[{"year":1991,"claim":"Cloning of ERK2 established the founding paradigm of a protein-serine/threonine kinase activated by tyrosine phosphorylation, answering how growth factor and insulin receptor tyrosine kinase signals are converted into serine/threonine phosphorylation cascades.","evidence":"Molecular cloning and biochemical kinase assays in insulin/NGF-stimulated cells","pmids":["2032290"],"confidence":"High","gaps":["Upstream activating kinase not yet identified","No substrates known at this stage"]},{"year":1992,"claim":"Positioning ERK2 downstream of oncogenic Ras resolved a critical gap in the Ras signaling pathway and explained how Ras transduces signals through cytoplasmic kinase cascades.","evidence":"Scrape-loading of p21ras into cells with ERK2 activity measurement; constitutive activation in Ras-transformed lines","pmids":["1371463"],"confidence":"High","gaps":["Direct intermediary kinases between Ras and ERK2 not defined","Mechanism of ERK2 activation (dual phosphorylation requirement) not yet established"]},{"year":1993,"claim":"Identification of cPLA2 and Elk-1 as direct ERK substrates answered what ERK2 phosphorylates, connecting the kinase to both lipid signaling (arachidonate release) and transcriptional activation (serum response element), and establishing the MAPK proline-directed phosphorylation motif.","evidence":"In vitro kinase assays with site-directed mutagenesis (cPLA2 Ser505; Elk-1 C-terminal domain) and functional readouts","pmids":["8381049","8386592"],"confidence":"High","gaps":["How ERK2 selects among multiple substrates unknown","Nuclear versus cytoplasmic substrate targeting mechanisms unresolved"]},{"year":1993,"claim":"Discovery that MKP-1 dephosphorylates both pThr and pTyr on ERK2 established the first negative-feedback mechanism for pathway termination, resolving how ERK2 is inactivated.","evidence":"In vitro phosphatase assay with catalytically inactive MKP-1 trapping phospho-ERK2 complex","pmids":["8221888"],"confidence":"High","gaps":["Relative contributions of different phosphatases in different cell contexts unknown","Spatial control of dephosphorylation not addressed"]},{"year":1997,"claim":"Identification of Smad1 and Mnk1/2 as ERK2 substrates expanded the functional scope, showing ERK2 antagonizes BMP signaling by blocking Smad nuclear entry and controls translation initiation through Mnk-eIF4E phosphorylation.","evidence":"In vitro phosphorylation with site mapping and nuclear localization assays (Smad1); co-IP and kinase assays (Mnk1/2)","pmids":["9335504","9155017"],"confidence":"High","gaps":["Whether ERK2 regulates all TGF-β superfamily Smads unknown","In vivo significance of Mnk pathway for translation control not tested"]},{"year":1998,"claim":"Crystal structure of phosphorylated ERK2 revealed the structural basis for dimerization and linked dimerization to nuclear accumulation, answering how activation-state controls subcellular distribution.","evidence":"X-ray crystallography combined with mutagenesis disrupting the dimer interface and microinjection nuclear translocation assays","pmids":["9604935"],"confidence":"High","gaps":["Whether dimerization is required for all nuclear functions unknown","Mechanism of nuclear import (importin involvement) not defined"]},{"year":1999,"claim":"Mapping of ERK2 residues 312–320 as a MEK1-dependent cytoplasmic retention signal and residues 321–327 as a nuclear translocation element resolved the molecular mechanism of ERK2 shuttling between nucleus and cytoplasm.","evidence":"GFP-fusion alanine-scanning mutagenesis with subcellular localization imaging","pmids":["10521408"],"confidence":"High","gaps":["Identity of nuclear import receptors interacting with residues 321–327 not determined","How phosphorylation releases the MEK1 anchor quantitatively not defined"]},{"year":1999,"claim":"Discovery that ERK2 phosphorylates Smad2/3 linker regions causing their cytoplasmic retention explained how oncogenic Ras signaling overrides TGF-β growth inhibition, a mechanism directly relevant to cancer biology.","evidence":"In vitro phosphorylation, mutagenesis, nuclear translocation and transcriptional reporter assays; Ras-resistant Smad3 mutant rescue","pmids":["10197981"],"confidence":"High","gaps":["Whether this mechanism operates in all Ras-driven cancers not established","Phosphatase that reverses ERK-mediated Smad phosphorylation unknown"]},{"year":2001,"claim":"Quantitative kinetic analysis showed dual phosphorylation increases ERK2 catalytic efficiency ~600,000-fold, primarily through enhancement of the phosphoryl transfer step, answering why dual (not single) phosphorylation is required for full activation.","evidence":"Steady-state kinetics and solvent viscosimetry with purified mono- and dually-phosphorylated ERK2","pmids":["11016942"],"confidence":"High","gaps":["Structural basis for the rate enhancement at the phosphoryl transfer step not resolved at atomic level","Contribution of each phosphosite individually not fully dissected"]},{"year":2003,"claim":"Mechanistic dissection of MKP3/DUSP6 revealed an intramolecular dephosphorylation mechanism within a 1:1 MKP3:pERK2 complex achieving >4000-fold rate enhancement, explaining the exquisite specificity and efficiency of ERK2 inactivation.","evidence":"In vitro phosphatase assay with chemical cross-linking, binding analyses, and engineered mutants","pmids":["14690430"],"confidence":"High","gaps":["Whether this intramolecular mechanism applies to all DUSPs unknown","Structural basis of catalytic activation within the complex not resolved"]},{"year":2004,"claim":"In vivo genetic studies established ERK2 as the predominant isoform for cardioprotection against ischemia-reperfusion injury and for T cell development/positive selection, answering whether ERK1 and ERK2 are functionally redundant.","evidence":"ERK2 heterozygous knockout mice with cardiac ischemia model; conditional ERK2 knockout with T cell developmental analysis","pmids":["15096454","16226508"],"confidence":"High","gaps":["Molecular basis for isoform-specific functions not resolved","Whether dose-dependence (ERK2 higher expression) explains non-redundancy not excluded"]},{"year":2005,"claim":"Identification of TSC2 as an ERK substrate whose phosphorylation disrupts the TSC1–TSC2 complex and activates mTOR signaling placed ERK2 as a direct link between Ras-MAPK and PI3K-mTOR pathways, resolving cross-talk relevant to cell growth and tumorigenesis.","evidence":"In vitro phosphorylation, co-IP, mutagenesis, and in vivo xenograft rescue with non-phosphorylatable TSC2","pmids":["15851026"],"confidence":"High","gaps":["Quantitative contribution of ERK vs. Akt-mediated TSC2 phosphorylation in different contexts unknown","Whether ERK2 and ERK1 have differential activity toward TSC2 not tested"]},{"year":2005,"claim":"Characterization of PEA-15 binding through a reverse DEJL motif blocking ERK2 substrate access, and scaffold functions of IQGAP1, established that ERK2 signaling output is determined not only by phosphorylation state but by competitive binding partners that sequester or localize the kinase.","evidence":"Fluorescence anisotropy binding assay and peptide displacement (PEA-15); pull-down with purified proteins, siRNA knockdown and kinase assay (IQGAP1)","pmids":["16324895","14970219"],"confidence":"High","gaps":["Full inventory of ERK2-sequestering proteins not available","Structural basis of PEA-15–ERK2 complex not determined at atomic resolution at this time"]},{"year":2012,"claim":"Discovery that ERK2 phosphorylates PKM2 at Ser37 to promote its nuclear translocation where PKM2 acts as β-catenin coactivator inducing c-Myc and the Warburg effect connected ERK2 directly to cancer metabolic reprogramming.","evidence":"In vitro kinase assay with docking site mutagenesis (Ile429/Leu431), nuclear fractionation, xenograft tumor model","pmids":["23178880"],"confidence":"High","gaps":["Whether this mechanism operates in all cancer types with activated ERK unknown","Other kinases that might redundantly phosphorylate PKM2 Ser37 not excluded"]},{"year":2014,"claim":"NMR relaxation dispersion experiments revealed that dual phosphorylation triggers global two-state conformational exchange (kex ~300 s⁻¹) throughout the kinase core, providing the biophysical mechanism underlying the massive catalytic rate enhancement and explaining how a distal phosphorylation event remodels the active site.","evidence":"¹³C side-chain methyl NMR relaxation dispersion on phosphorylated and unphosphorylated ERK2","pmids":["24550275"],"confidence":"High","gaps":["How substrate binding shifts the conformational equilibrium not determined","Whether conformational dynamics differ for different substrate classes unknown"]},{"year":2015,"claim":"A dimerization-disrupting small molecule showed that ERK2 dimerization specifically governs extranuclear (cytoplasmic) signaling and RAS-driven tumorigenesis without affecting nuclear ERK functions, resolving the long-standing question of what dimer-dependent signaling actually controls.","evidence":"Small molecule ERK dimerization inhibitor with dimerization assays, cancer cell transformation assays, and mouse tumor models","pmids":["26267534"],"confidence":"High","gaps":["Identity of dimer-specific extranuclear substrates not fully catalogued","Whether monomer-selective inhibition spares normal tissue functions unknown"]},{"year":2017,"claim":"An unbiased CRISPR screen in BRAF-inhibitor-resistant melanoma identified ERK2 as the kinase driving a phenotype switch (EMT-like, MITF shutdown) through JUNB/FRA1 upon drug withdrawal, establishing ERK2's role in therapy-induced adaptive plasticity.","evidence":"Genome-wide CRISPR-Cas9 knockout screen, transcriptomics, mouse tumor models, patient sample validation","pmids":["28976960"],"confidence":"High","gaps":["Whether ERK1 can substitute for ERK2 in drug-addiction phenotype not fully resolved","Direct ERK2 substrates mediating the MITF shutdown not identified"]},{"year":2020,"claim":"ERK2-mediated phosphorylation of ULK1 leading to its BTRC-dependent ubiquitination and proteasomal degradation linked ERK2 to suppression of mitophagy, accumulation of ROS-generating mitochondria, NLRP3 inflammasome activation, and breast cancer bone metastasis.","evidence":"In vitro kinase assay, ubiquitination assay, MEK inhibitor trametinib, xenograft bone metastasis model","pmids":["33213267"],"confidence":"High","gaps":["Whether this mechanism is specific to breast cancer or generalizable unknown","Relative contribution of ERK1 vs ERK2 to ULK1 phosphorylation not dissected"]},{"year":2023,"claim":"ChIP-seq revealed ERK2 binds directly to gene promoters as a bidirectional transcription factor in gastric cancer cells, expanding its role beyond kinase to include direct DNA-binding transcriptional regulation.","evidence":"ChIP-seq, ChIP assay, RNA-seq, cell migration/invasion assays in gastric cancer cells","pmids":["37817112"],"confidence":"Medium","gaps":["DNA-binding domain or motif within ERK2 not identified","Whether this transcription factor function occurs in non-cancer contexts unknown","Independent replication in other cell types needed"]},{"year":null,"claim":"Major open questions include the structural basis for isoform-specific (ERK2 vs ERK1) substrate selectivity, comprehensive identification of dimer-dependent versus monomer-dependent substrates, and the mechanism and physiological relevance of ERK2's direct DNA-binding transcription factor activity.","evidence":"","pmids":[],"confidence":"High","gaps":["Structural explanation for ERK2/ERK1 non-redundancy lacking","Complete dimer-specific substrate catalog unavailable","ERK2 DNA-binding mechanism unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,3,5,6,7,10,11,12,15,16,17,22,26,30,37,39,40,43,47,50]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,15,26]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[15,27]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[52]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[52]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9,28,44]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,9,52]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[8,52]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[34]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[31]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,6,7,13,18,21,25,44,48]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[29,35]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[23,24,46]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[34,50]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[29,35]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,10,17,37,52]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,39,46]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[41,48]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[40,50]}],"complexes":["Raf-MEK-ERK cascade module","β-arrestin/ERK2 signalosome"],"partners":["MAP2K1","IQGAP1","PEA15","DUSP6","DUSP1","PTPN7","PARP1","GAB1"],"other_free_text":[]},"mechanistic_narrative":"MAPK1/ERK2 is a central serine/threonine kinase in the Ras–Raf–MEK–ERK signaling cascade that transduces mitogenic, stress, and mechanical stimuli into phosphorylation of a broad substrate repertoire controlling proliferation, differentiation, survival, metabolism, cytoskeletal dynamics, and autophagy. Dual phosphorylation at Thr185/Tyr187 by MEK1/2 increases catalytic efficiency approximately 600,000-fold by inducing global conformational exchange dynamics that enable active-site domain closure, and promotes ERK2 homodimerization required for extranuclear signaling and nuclear translocation [PMID:11016942, PMID:24550275, PMID:9604935, PMID:26267534]. In the nucleus, ERK2 phosphorylates transcription factors including Elk-1, Sp1, C/EBPβ, ETV3, NANOG, and Beta2/PDX-1, and can also bind gene promoters directly as a transcription factor; in the cytoplasm, it phosphorylates cPLA2, Smad1/2/3, TSC2, PKM2, RhoA, ULK1, PAK1, Bcl3, and dynein, linking ERK2 to arachidonate release, TGF-β/BMP antagonism, mTOR activation, the Warburg effect, protein turnover, mitophagy, and lipid droplet biogenesis [PMID:8381049, PMID:15851026, PMID:23178880, PMID:33213267, PMID:37817112]. ERK2 activity is spatially controlled by cytoplasmic retention through MEK1 binding (residues 312–320) and inhibitory partners PEA-15 and Naf1α, and temporally controlled by dual-specificity phosphatases MKP-1, MKP3/DUSP6, and HePTP, while scaffold proteins β-arrestin/arrestin-2 and IQGAP1 direct pathway-specific signaling outputs [PMID:10521408, PMID:8221888, PMID:14690430, PMID:14970219, PMID:14769794]."},"prefetch_data":{"uniprot":{"accession":"P28482","full_name":"Mitogen-activated protein kinase 1","aliases":["ERT1","Extracellular signal-regulated kinase 2","ERK-2","MAP kinase isoform p42","p42-MAPK","Mitogen-activated protein kinase 2","MAP kinase 2","MAPK 2"],"length_aa":360,"mass_kda":41.4,"function":"Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1 and FXR1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in response to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation. Phosphorylates CDK2AP2 (By similarity). Phosphorylates phosphoglycerate kinase PGK1 under hypoxic conditions to promote its targeting to the mitochondrion and suppress the formation of acetyl-coenzyme A from pyruvate (PubMed:26942675). Phosphorylates GJA1 at 'Ser-279' and 'Ser-282' resulting in an increase in GJA1 ubiquitination and ultimately lysosomal degradation (By similarity) Acts as a transcriptional repressor. Binds to a [GC]AAA[GC] consensus sequence. Repress the expression of interferon gamma-induced genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity is independent of kinase activity","subcellular_location":"Cytoplasm, cytoskeleton, spindle; Nucleus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm; Membrane, caveola; Cell junction, focal adhesion","url":"https://www.uniprot.org/uniprotkb/P28482/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAPK1","classification":"Not Classified","n_dependent_lines":172,"n_total_lines":1208,"dependency_fraction":0.1423841059602649},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000100030","cell_line_id":"CID001201","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"CAPZB","stoichiometry":4.0},{"gene":"MECP2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001201","total_profiled":1310},"omim":[{"mim_id":"621174","title":"CHOLESIN; CHLSN","url":"https://www.omim.org/entry/621174"},{"mim_id":"621173","title":"G PROTEIN-COUPLED RECEPTOR 146; GPR146","url":"https://www.omim.org/entry/621173"},{"mim_id":"621172","title":"RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 39; ARHGEF39","url":"https://www.omim.org/entry/621172"},{"mim_id":"621142","title":"CHROMOSOME 15 OPEN READING FRAME 39; C15ORF39","url":"https://www.omim.org/entry/621142"},{"mim_id":"621120","title":"DELTA-LIKE NONCANONICAL NOTCH LIGAND 2; DLK2","url":"https://www.omim.org/entry/621120"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Microtubules","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MAPK1"},"hgnc":{"alias_symbol":["ERK","ERK2","p41mapk","MAPK2"],"prev_symbol":["PRKM2","PRKM1"]},"alphafold":{"accession":"P28482","domains":[{"cath_id":"3.30.200.20","chopping":"13-106_336-353","consensus_level":"high","plddt":93.7172,"start":13,"end":353},{"cath_id":"1.10.510.10","chopping":"109-308","consensus_level":"high","plddt":90.7579,"start":109,"end":308}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28482","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28482-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28482-F1-predicted_aligned_error_v6.png","plddt_mean":90.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAPK1","jax_strain_url":"https://www.jax.org/strain/search?query=MAPK1"},"sequence":{"accession":"P28482","fasta_url":"https://rest.uniprot.org/uniprotkb/P28482.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28482/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28482"}},"corpus_meta":[{"pmid":"9604935","id":"PMC_9604935","title":"Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9604935","citation_count":580,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1371463","id":"PMC_1371463","title":"Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1371463","citation_count":518,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17496910","id":"PMC_17496910","title":"Integrating signals from RTKs to ERK/MAPK.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17496910","citation_count":479,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18562239","id":"PMC_18562239","title":"The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18562239","citation_count":378,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17244536","id":"PMC_17244536","title":"DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17244536","citation_count":284,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16226508","id":"PMC_16226508","title":"The role of erk1 and erk2 in multiple stages of T cell development.","date":"2005","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16226508","citation_count":280,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17085074","id":"PMC_17085074","title":"ERK2: a logical AND gate critical for drug-induced plasticity?","date":"2006","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17085074","citation_count":278,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18594198","id":"PMC_18594198","title":"Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease.","date":"2008","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/18594198","citation_count":242,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27376062","id":"PMC_27376062","title":"ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?","date":"2016","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27376062","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16139248","id":"PMC_16139248","title":"Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16139248","citation_count":203,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15096454","id":"PMC_15096454","title":"MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo.","date":"2004","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/15096454","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14970219","id":"PMC_14970219","title":"IQGAP1 binds ERK2 and modulates its activity.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14970219","citation_count":189,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9918860","id":"PMC_9918860","title":"Sp1 phosphorylation by Erk 2 stimulates DNA binding.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9918860","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25831013","id":"PMC_25831013","title":"Mitophagy is primarily due to alternative autophagy and requires the MAPK1 and MAPK14 signaling pathways.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25831013","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33213267","id":"PMC_33213267","title":"MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33213267","citation_count":174,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19017950","id":"PMC_19017950","title":"The Erk2 MAPK regulates CD8 T cell proliferation and survival.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19017950","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14974085","id":"PMC_14974085","title":"Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/14974085","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28675784","id":"PMC_28675784","title":"A compendium of ERK targets.","date":"2017","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/28675784","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16723731","id":"PMC_16723731","title":"PLD1 and ERK2 regulate cytosolic lipid droplet formation.","date":"2006","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16723731","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15531431","id":"PMC_15531431","title":"Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways.","date":"2004","source":"Environmental health perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/15531431","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12810726","id":"PMC_12810726","title":"Regulation of insulin gene transcription by ERK1 and ERK2 in pancreatic beta cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12810726","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10521408","id":"PMC_10521408","title":"Identification of a cytoplasmic-retention sequence in ERK2.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10521408","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7803762","id":"PMC_7803762","title":"The mitogen-activated protein kinases, ERK1 and ERK2.","date":"1994","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/7803762","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32494004","id":"PMC_32494004","title":"CircRNA_101237 promotes NSCLC progression via the miRNA-490-3p/MAPK1 axis.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32494004","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28976960","id":"PMC_28976960","title":"Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28976960","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22028470","id":"PMC_22028470","title":"Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22028470","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26267534","id":"PMC_26267534","title":"Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.","date":"2015","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/26267534","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24691442","id":"PMC_24691442","title":"Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24691442","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10030673","id":"PMC_10030673","title":"Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10030673","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10969079","id":"PMC_10969079","title":"MEKK1 binds raf-1 and the ERK2 cascade components.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10969079","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8947482","id":"PMC_8947482","title":"Calcium-dependent activation of Erk-1 and Erk-2 after hypo-osmotic astrocyte swelling.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8947482","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26235619","id":"PMC_26235619","title":"Functional Redundancy of ERK1 and ERK2 MAP Kinases during Development.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26235619","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26190261","id":"PMC_26190261","title":"ERK2 Mediates Metabolic Stress Response to Regulate Cell Fate.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26190261","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14769794","id":"PMC_14769794","title":"Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14769794","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23871831","id":"PMC_23871831","title":"A new mechanism of RhoA ubiquitination and degradation: roles of SCF(FBXL19) E3 ligase and Erk2.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23871831","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29125598","id":"PMC_29125598","title":"A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29125598","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17298299","id":"PMC_17298299","title":"Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets.","date":"2007","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17298299","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11404250","id":"PMC_11404250","title":"Involvement of the MAP kinase ERK2 in MUC1 mucin signaling.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11404250","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11016942","id":"PMC_11016942","title":"Mechanism of activation of ERK2 by dual phosphorylation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11016942","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24125755","id":"PMC_24125755","title":"FGF2 stimulates osteogenic differentiation through ERK induced TAZ expression.","date":"2013","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/24125755","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19961364","id":"PMC_19961364","title":"Key role of ERK pathway signaling in lupus.","date":"2010","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19961364","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37298618","id":"PMC_37298618","title":"MAPK-ERK Pathway.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37298618","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21159167","id":"PMC_21159167","title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21159167","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25401279","id":"PMC_25401279","title":"ERK1 and ERK2 regulate chondrocyte terminal differentiation during endochondral bone formation.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25401279","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23983265","id":"PMC_23983265","title":"Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23983265","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24550275","id":"PMC_24550275","title":"Phosphorylation releases constraints to domain motion in ERK2.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24550275","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11500490","id":"PMC_11500490","title":"ERK2- and p90(Rsk2)-dependent pathways regulate the CCAAT/enhancer-binding protein-beta interaction with serum response factor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11500490","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18514184","id":"PMC_18514184","title":"Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulation.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18514184","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15542607","id":"PMC_15542607","title":"Adhesion stimulates direct PAK1/ERK2 association and leads to ERK-dependent PAK1 Thr212 phosphorylation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15542607","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28393232","id":"PMC_28393232","title":"MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28393232","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26117268","id":"PMC_26117268","title":"HOTAIR Interacting with MAPK1 Regulates Ovarian Cancer skov3 Cell Proliferation, Migration, and Invasion.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/26117268","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29760222","id":"PMC_29760222","title":"ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29760222","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23657295","id":"PMC_23657295","title":"S-nitrosylation of ERK inhibits ERK phosphorylation and induces apoptosis.","date":"2013","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/23657295","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28302472","id":"PMC_28302472","title":"ERK1 and ERK2 activation modulates diet-induced obesity in mice.","date":"2017","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/28302472","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30808963","id":"PMC_30808963","title":"Silencing of spinal Trpv1 attenuates neuropathic pain in rats by inhibiting CAMKII expression and ERK2 phosphorylation.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30808963","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28689659","id":"PMC_28689659","title":"Bcl3 Phosphorylation by Akt, Erk2, and IKK Is Required for Its Transcriptional Activity.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28689659","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15851480","id":"PMC_15851480","title":"Differential Involvement of ERK2 and p38 in platelet adhesion to collagen.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15851480","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18442396","id":"PMC_18442396","title":"ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish embryogenesis.","date":"2008","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18442396","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18378228","id":"PMC_18378228","title":"ERK2 protein regulates the proliferation of human mesenchymal stem cells without affecting their mobilization and differentiation potential.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18378228","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24678451","id":"PMC_24678451","title":"NANOG is multiply phosphorylated and directly modified by ERK2 and CDK1 in vitro.","date":"2014","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24678451","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30049820","id":"PMC_30049820","title":"Outstanding questions in developmental ERK signaling.","date":"2018","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30049820","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29118671","id":"PMC_29118671","title":"miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1.","date":"2017","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/29118671","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20739576","id":"PMC_20739576","title":"Genetic targeting of ERK1 suggests a predominant role for ERK2 in murine pain models.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20739576","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16045329","id":"PMC_16045329","title":"Proximity-induced catalysis by the protein kinase ERK2.","date":"2005","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/16045329","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29335299","id":"PMC_29335299","title":"HOTAIR contributes to cell proliferation and metastasis of cervical cancer via targetting miR-23b/MAPK1 axis.","date":"2018","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/29335299","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31075732","id":"PMC_31075732","title":"miR-141-5p regulate ATF2 via effecting MAPK1/ERK2 signaling to promote preeclampsia.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31075732","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30693181","id":"PMC_30693181","title":"Gene Silencing via PDA/ERK2-siRNA-Mediated Electrospun Fibers for Peritendinous Antiadhesion.","date":"2018","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/30693181","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26336084","id":"PMC_26336084","title":"ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1.","date":"2015","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/26336084","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26884868","id":"PMC_26884868","title":"MAPK1 up-regulates the expression of MALAT1 to promote the proliferation of cardiomyocytes through PI3K/AKT signaling pathway.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26884868","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29137432","id":"PMC_29137432","title":"MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29137432","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20825492","id":"PMC_20825492","title":"ERK1 and ERK2 are required for radial glial maintenance and cortical lamination.","date":"2010","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/20825492","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23271465","id":"PMC_23271465","title":"Proteomic and functional analyses reveal MAPK1 regulates milk protein synthesis.","date":"2012","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/23271465","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20922792","id":"PMC_20922792","title":"Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal.","date":"2010","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/20922792","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18597688","id":"PMC_18597688","title":"TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.","date":"2008","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18597688","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32110054","id":"PMC_32110054","title":"Circ_0058124 Upregulates MAPK1 Expression to Promote Proliferation, Metastasis and Metabolic Abilities in Thyroid Cancer Through Sponging miR-940.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32110054","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32231737","id":"PMC_32231737","title":"Circular RNA MAN2B2 promotes cell proliferation of hepatocellular carcinoma cells via the miRNA-217/MAPK1 axis.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32231737","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32187556","id":"PMC_32187556","title":"Mechanical Stress Regulates Epithelial Tissue Integrity and Stiffness through the FGFR/Erk2 Signaling Pathway during Embryogenesis.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32187556","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31311868","id":"PMC_31311868","title":"Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31311868","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10593929","id":"PMC_10593929","title":"Activated ERK2 interacts with and phosphorylates the docking protein GAB1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10593929","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12220502","id":"PMC_12220502","title":"A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12220502","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14690430","id":"PMC_14690430","title":"Intramolecular dephosphorylation of ERK by MKP3.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14690430","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32471201","id":"PMC_32471201","title":"Liver Fibrosis and Inflammation under the Control of ERK2.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32471201","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26861188","id":"PMC_26861188","title":"Naringenin targets ERK2 and suppresses UVB-induced photoaging.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26861188","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21985012","id":"PMC_21985012","title":"Resting and active states of the ERK2:HePTP complex.","date":"2011","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/21985012","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28992617","id":"PMC_28992617","title":"Iodine Promotes Tumorigenesis of Thyroid Cancer by Suppressing Mir-422a and Up-Regulating MAPK1.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28992617","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28512266","id":"PMC_28512266","title":"Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28512266","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36103025","id":"PMC_36103025","title":"LINC00511 promotes cervical cancer progression by regulating the miR-497-5p/MAPK1 axis.","date":"2022","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/36103025","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29928348","id":"PMC_29928348","title":"Activation of the SphK1/ERK/p-ERK pathway promotes autophagy in colon cancer cells.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29928348","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23820584","id":"PMC_23820584","title":"KRAS and MAPK1 gene amplification in type II ovarian carcinomas.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23820584","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34668273","id":"PMC_34668273","title":"EZH2 upregulates the expression of MAPK1 to promote intervertebral disc degeneration via suppression of miR-129-5p.","date":"2022","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34668273","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26259804","id":"PMC_26259804","title":"Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.","date":"2015","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/26259804","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28860596","id":"PMC_28860596","title":"MAPK1 of Leishmania donovani interacts and phosphorylates HSP70 and HSP90 subunits of foldosome complex.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28860596","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16420578","id":"PMC_16420578","title":"ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X.","date":"2006","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/16420578","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37714159","id":"PMC_37714159","title":"An improved Erk biosensor detects oscillatory Erk dynamics driven by mitotic erasure during early development.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/37714159","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25730857","id":"PMC_25730857","title":"Structural assembly of the signaling competent ERK2-RSK1 heterodimeric protein kinase complex.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25730857","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33537828","id":"PMC_33537828","title":"MicroRNA‑186‑5p downregulation inhibits osteoarthritis development by targeting MAPK1.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33537828","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11679970","id":"PMC_11679970","title":"Defective mitogen-activated protein kinase (ERK2) signaling in gastric mucosa of portal hypertensive rats: potential therapeutic implications.","date":"2001","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11679970","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16324895","id":"PMC_16324895","title":"Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16324895","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37817112","id":"PMC_37817112","title":"MAPK1 promotes the metastasis and invasion of gastric cancer as a bidirectional transcription factor.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37817112","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23970301","id":"PMC_23970301","title":"Autophagy is used as a survival program in unfertilized sea urchin eggs that are destined to die by apoptosis after inactivation of MAPK1/3 (ERK2/1).","date":"2013","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/23970301","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21833088","id":"PMC_21833088","title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21833088","citation_count":2101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2032290","id":"PMC_2032290","title":"ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF.","date":"1991","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2032290","citation_count":1747,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8381049","id":"PMC_8381049","title":"cPLA2 is phosphorylated and activated by MAP kinase.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8381049","citation_count":1729,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8386592","id":"PMC_8386592","title":"The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8386592","citation_count":1219,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26627737","id":"PMC_26627737","title":"High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26627737","citation_count":1200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8221888","id":"PMC_8221888","title":"MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8221888","citation_count":1086,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15851026","id":"PMC_15851026","title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15851026","citation_count":1067,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11520933","id":"PMC_11520933","title":"Nerve growth factor signaling, neuroprotection, and neural repair.","date":"2001","source":"Annual review of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11520933","citation_count":1029,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10567572","id":"PMC_10567572","title":"BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10567572","citation_count":920,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15592455","id":"PMC_15592455","title":"Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.","date":"2004","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/15592455","citation_count":916,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17496918","id":"PMC_17496918","title":"The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17496918","citation_count":883,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10197981","id":"PMC_10197981","title":"A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras.","date":"1999","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/10197981","citation_count":843,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9687510","id":"PMC_9687510","title":"Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9687510","citation_count":842,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9204908","id":"PMC_9204908","title":"Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9204908","citation_count":813,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9155017","id":"PMC_9155017","title":"Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9155017","citation_count":791,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23178880","id":"PMC_23178880","title":"ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect.","date":"2012","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23178880","citation_count":769,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9335504","id":"PMC_9335504","title":"Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9335504","citation_count":752,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10490027","id":"PMC_10490027","title":"Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10490027","citation_count":723,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11226259","id":"PMC_11226259","title":"Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11226259","citation_count":685,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47741,"output_tokens":9577,"usd":0.143439},"stage2":{"model":"claude-opus-4-6","input_tokens":13552,"output_tokens":4444,"usd":0.26829},"total_usd":0.896598,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60256,"output_tokens":11590,"usd":0.177309},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":15983,"output_tokens":5005,"usd":0.30756}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Phosphorylated ERK2 forms homodimers with phosphorylated and unphosphorylated ERK2 partners; disruption of dimerization by mutagenesis reduces nuclear accumulation, demonstrating that dimerization is essential for ligand-dependent nuclear translocation. Crystal structure of phosphorylated ERK2 reveals the structural basis for dimerization.\",\n      \"method\": \"Microinjection, site-directed mutagenesis, crystal structure determination\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis plus functional nuclear translocation assay in single rigorous study\",\n      \"pmids\": [\"9604935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Oncogenic p21ras activates ERK2 (42 kDa MAP kinase) via phosphorylation on tyrosine and threonine, placing ERK2 downstream of Ras in a signal transduction pathway activated independently of growth factors.\",\n      \"method\": \"Scrape-loading of p21ras protein into quiescent cells, kinase activity assay, phosphoamino acid analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay establishing ERK2 as a Ras effector, foundational study with >500 citations\",\n      \"pmids\": [\"1371463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Dual phosphorylation of ERK2 at conserved threonine and tyrosine residues increases overall catalytic efficiency ~600,000-fold and turnover rate ~50,000-fold, primarily by enhancing the rate of phosphoryl group transfer (~60,000-fold), with moderate decreases in Kd for ATP and substrate.\",\n      \"method\": \"In vitro kinase assay, solvent viscosometric studies, kinetic analysis of wild-type vs. phosphorylated ERK2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — detailed in vitro reconstitution with kinetic dissection of individual catalytic steps\",\n      \"pmids\": [\"11016942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A cytoplasmic-retention sequence in ERK2 (residues 312–320, especially acidic residues at positions 316, 319, and 320) mediates MEK1-dependent cytosolic retention, while residues 321–327 are required for mitogen-stimulated nuclear translocation.\",\n      \"method\": \"GFP-ERK2 fusion expression in CHO cells, alanine-scanning mutagenesis, co-expression with MEK1, live-cell imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with localization imaging identifies specific residues for cytoplasmic retention and nuclear import\",\n      \"pmids\": [\"10521408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Phosphorylation of ERK2 by MAP kinase kinase 1 induces global conformational exchange dynamics throughout the conserved kinase core (microsecond-to-millisecond timescale), shifting from localized side-chain motions in inactive ERK2 to a two-state global domain motion in active ERK2, consistent with release of constraints at the interdomain hinge.\",\n      \"method\": \"NMR 13C relaxation dispersion of methyl side chains, hinge-region mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural dynamics with mutagenesis validation in a single rigorous study\",\n      \"pmids\": [\"24550275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Phosphorylated ERK2 directly interacts with and activates PARP-1 in a DNA-damage-independent manner; the activated PARP-1 in turn dramatically enhances ERK2-catalyzed phosphorylation of the transcription factor Elk1, and this cascade promotes histone acetylation and c-fos transcription in cortical neurons and cardiomyocytes.\",\n      \"method\": \"Cell-free system with recombinant proteins, co-immunoprecipitation, kinase assay, reporter gene assay in primary neurons and cardiomyocytes\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstituted in vitro interaction plus functional validation in primary cells with multiple readouts\",\n      \"pmids\": [\"17244536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IQGAP1 directly binds ERK2 (demonstrated with purified proteins and endogenous co-immunoprecipitation); manipulation of IQGAP1 levels modulates growth factor-stimulated ERK1/2 activity, and an IQGAP1 construct lacking the ERK2-binding region fails to interfere with ERK activation.\",\n      \"method\": \"In vitro pull-down with purified proteins, endogenous co-immunoprecipitation from breast epithelial cells, ERK kinase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct in vitro binding with purified proteins confirmed by endogenous co-IP plus functional modulation\",\n      \"pmids\": [\"14970219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Using analog-sensitive ERK2 engineered to use an ATP analog, 80 direct ERK2 substrates were identified in vitro; among novel substrates, the transcription factor ETV3 is phosphorylated by ERK2 on canonical and non-canonical motifs, and this phosphorylation prevents ETV3 from binding DNA at thousands of gene promoters, including those involved in negative feedback of upstream signals.\",\n      \"method\": \"Chemical-genetic substrate tagging with analog-sensitive ERK2, mass spectrometry, ChIP-seq, transcriptional reporter assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — chemical genetic in vitro labeling plus genome-wide ChIP-seq validation with multiple orthogonal methods\",\n      \"pmids\": [\"22028470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Endogenous MEKK1 binds directly to endogenous ERK2, MEK1, and Raf-1, demonstrating that MEKK1 can scaffold the entire ERK2 MAP kinase module (MEKK→MEK1→ERK2).\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — endogenous co-IP without in vitro reconstitution; single lab\",\n      \"pmids\": [\"10969079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MKP3 (a dual-specificity phosphatase) dephosphorylates pERK2 via an intramolecular mechanism: a monomer of MKP3 binds a monomer of pERK2, forming a heterodimer within which MKP3 performs intramolecular dephosphorylation, yielding a ≥4000-fold rate enhancement (kcat/Km).\",\n      \"method\": \"Kinetic analysis, chemical cross-linking, ERK2 and MKP3 mutants, binding analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — detailed mechanistic in vitro reconstitution with mutants, cross-linking, and kinetics defining stoichiometry and mechanism\",\n      \"pmids\": [\"14690430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERK2 phosphorylates the transcription factor Sp1 in vitro, and this phosphorylation stimulates Sp1 DNA binding; EGF/Ras/ERK2 signaling targets Sp1 to activate the gastrin promoter via a GC-rich element (gERE).\",\n      \"method\": \"In vitro kinase/phosphorylation assay with recombinant ERK2, electrophoretic mobility shift assay, co-transfection reporter assay with dominant-negative constructs and MEK inhibitor\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro phosphorylation plus co-transfection epistasis; single lab\",\n      \"pmids\": [\"9918860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ERK1/2 are required for glucose-stimulated insulin gene transcription; ERK2 phosphorylates the transcription factors Beta2/NeuroD1 and PDX-1, increasing their transactivation activity and cumulatively activating the rat insulin I promoter.\",\n      \"method\": \"Dominant-negative ERK2, MEK inhibitors, overexpression of ERK2, transfection in islets and beta cell lines, reporter assay, kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal approaches (dominant-negative, pharmacological inhibition, overexpression, kinase assay) in primary islets\",\n      \"pmids\": [\"12810726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Nonapoptotic programmed cell death mediated by the NK1R receptor involves a scaffold protein arrestin 2 that recruits Raf-1→MEK2→ERK2, leading to phosphorylation of the orphan nuclear receptor Nur77; this ERK2/MEK2-specific pathway (not ERK1/MEK1) is required for Substance P-induced nonapoptotic cell death.\",\n      \"method\": \"Dominant-negative arrestin 2, RNAi targeting ERK2 vs ERK1 and MEK2 vs MEK1, MEK inhibitors, kinase epistasis in primary striatal neurons\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific RNAi plus dominant-negative constructs with epistasis in primary neurons, multiple orthogonal methods\",\n      \"pmids\": [\"14769794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Adhesion signaling stimulates direct physical association between PAK1 and ERK2; ERK2 phosphorylates PAK1 at Thr212 in vitro and in cells in an adhesion- and MEK-dependent manner; PAK1-T212 phosphorylation by ERK2 provides a negative feedback signal attenuating downstream ERK signaling.\",\n      \"method\": \"Co-immunoprecipitation from smooth muscle cells, far-Western analysis, peptide mapping, in vitro kinase assay, phosphomimic mutant expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding by far-Western, in vitro kinase assay identifying phosphorylation site, confirmed in cells with phosphomimic mutant\",\n      \"pmids\": [\"15542607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Phosphorylated ERK2 (pERK2) directly and exclusively associates with GAB1 (without requiring a bridging protein); ERK2 phosphorylates both the MET-binding domain and full-length GAB1 in vitro, and GAB1 serine phosphorylation is increased in cells by constitutively active MEK1.\",\n      \"method\": \"Pull-down with bacterially expressed proteins, co-immunoprecipitation, in vitro kinase assay, phosphopeptide mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding demonstrated with purified proteins, in vitro phosphorylation with site mapping, confirmed in intact cells\",\n      \"pmids\": [\"10593929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ERK2 (but not ERK1, JNK1, JNK2, p38α, or p38β) is specifically required for basal and insulin-stimulated cytosolic lipid droplet formation; ERK2 acts downstream of PLD1 and phosphorylates dynein, increasing dynein localization on ADRP-containing lipid droplets, and dynein is required for lipid droplet formation.\",\n      \"method\": \"siRNA knockdown, overexpression, microinjection, pharmacological inhibition, cell-free lipid droplet formation assay, kinase assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — isoform-specific knockdown plus reconstitution in cell-free system, identification of dynein as ERK2 substrate\",\n      \"pmids\": [\"16723731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK2 uses a proximity-induced (docking-mediated) catalytic mechanism: the pnt domain of substrate EtsDelta138 docks ERK2 outside the active site, increasing the local concentration of the TP phosphorylation motif; mutation of the TP motif decreases kcat without affecting ternary complex stability, while disruption of the pnt domain reduces binding 10-fold without affecting kcat.\",\n      \"method\": \"In vitro kinase assay with mutant substrates and ERK2, kinetic analysis\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro reconstitution with mutagenesis and kinetic dissection\",\n      \"pmids\": [\"16045329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"X-ray crystal structure of human ERK2 in complex with the selective inhibitor FR180204 identifies Q105, D106, L156, and C166 as key residues forming the ATP-binding pocket critical for drug-protein interaction; FR180204 acts as an ATP-competitive inhibitor with Ki values of 0.31 µM (ERK1) and 0.14 µM (ERK2).\",\n      \"method\": \"X-ray crystallography, Lineweaver-Burk kinetic analysis, cell-based luciferase reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus kinetic mechanism determination\",\n      \"pmids\": [\"16139248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mitochondrial localization of ERK2 activity is sufficient to induce mitophagy and autophagic cell stress; constitutively active ERK2-CA localizes more extensively to mitochondria than ERK2-WT, and kinase-deficient ERK2-KD does not localize to mitochondria or induce mitophagy, demonstrating that kinase activity drives mitochondrial targeting and mitophagic degradation.\",\n      \"method\": \"GFP-ERK2 fusion constructs (WT, CA, KD), transfection, colocalization with mitochondrial and autophagolysosomal markers, LC3 and bafilomycin autophagy assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment linked to functional consequence using multiple genetic variants; single lab\",\n      \"pmids\": [\"18594198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK2 (MAPK1) and p38 (MAPK14) are both required for mitophagy induced by starvation or hypoxia; this mitophagy predominantly proceeds through an alternative autophagy pathway (RAB9A/RAB9B-dependent) rather than conventional macroautophagy, and knockdown of MAPK1 suppresses it.\",\n      \"method\": \"Keima-based mitophagy assay, siRNA knockdown of MAPK1/MAPK14, ATG5 KO MEFs, RAB9A/B knockdown\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown with defined phenotypic readout and pathway placement; single lab\",\n      \"pmids\": [\"25831013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MAPK1/ERK2 (together with MAPK3/ERK1) phosphorylates ULK1, triggering its interaction with the E3 ligase adaptor BTRC and subsequent K48-linked ubiquitination and proteasomal degradation, thereby attenuating mitophagy.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, ubiquitination assay, MEK inhibitor rescue (trametinib), shRNA knockdown\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay plus ubiquitination assay plus pharmacological rescue with multiple orthogonal approaches\",\n      \"pmids\": [\"33213267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERK2 (but not ERK1) selectively phosphorylates the transcription factor C/EBPβ at a consensus MAPK site in vitro, and this phosphorylation is required for Ras-stimulated C/EBPβ-SRF interaction and transactivation of the serum response element; dominant-negative ERK2 (but not dominant-negative ERK1) blocks this interaction.\",\n      \"method\": \"In vitro kinase assay with recombinant ERK1 and ERK2, dominant-negative ERK constructs, co-immunoprecipitation, luciferase reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro phosphorylation demonstrating ERK2 isoform specificity, confirmed by isoform-selective dominant-negatives\",\n      \"pmids\": [\"11500490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERK2-mediated phosphorylation of RhoA is both sufficient and required for SCF(FBXL19) E3 ligase-mediated RhoA ubiquitination at Lys135 and proteasomal degradation; a RhoA K135R mutant is resistant to this ubiquitination.\",\n      \"method\": \"In vitro kinase assay, ubiquitination assay, site-directed mutagenesis (K135R), overexpression and knockdown of FBXL19\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay coupled with ubiquitination assay and mutagenesis identifying the ubiquitination site\",\n      \"pmids\": [\"23871831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ERK2 phosphorylates Bcl3 at Ser114 and Ser446 (IKK1/2 phosphorylates the same sites), converting Bcl3 from an IκB-like inhibitor into a transcriptional coregulator by facilitating its recruitment to DNA; cells expressing S114A/S446A Bcl3 show proliferation and migration defects.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, transcriptional reporter assay, cell proliferation/migration assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay with mutagenesis plus functional cellular readouts\",\n      \"pmids\": [\"28689659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ERK2 and CDK1/CyclinA2 directly phosphorylate NANOG at specific sites; this was identified using the multiplexed assay for kinase specificity (MAKS) that simultaneously tests multiple kinases and maps exact phosphorylation sites.\",\n      \"method\": \"MAKS in vitro kinase specificity assay, mass spectrometry, phosphosite mapping on endogenous NANOG\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with direct phosphosite identification; single lab, functional consequences not fully established\",\n      \"pmids\": [\"24678451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of the ERK2–RSK1 heterodimeric complex reveals a precatalytic state in which the activation loop of RSK1 faces ERK2's catalytic site; the MAPK-binding linear motif of RSK1 interacting with the ERK2 docking groove is the primary determinant of the encounter complex, with kinase domain surface contacts enabling the catalytically competent state.\",\n      \"method\": \"X-ray crystallography, molecular dynamics simulation, biochemical binding assays, cellular signaling assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with MD simulation and biochemical validation\",\n      \"pmids\": [\"25730857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK inhibitors Vertex-11e and SCH772984 act as conformation-selective inhibitors that exploit the two-state equilibrium (L and R states) of active 2P-ERK2, shifting it in opposing directions; X-ray structures and HX-MS show these inhibitors differentially affect domain closure at the active site and activation loop conformation, consequently controlling MAP kinase phosphatase accessibility to 2P-ERK2.\",\n      \"method\": \"NMR, X-ray crystallography, hydrogen-exchange mass spectrometry, phosphatase activity assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple structural methods (X-ray, NMR, HX-MS) plus functional phosphatase assay\",\n      \"pmids\": [\"31311868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S-nitrosylation of ERK by nitric oxide at Cys183 inhibits ERK phosphorylation and triggers apoptosis; an S-nitrosylation-dead mutant C183A abolishes the pro-apoptotic effect of NO and favors cell survival.\",\n      \"method\": \"S-nitrosylation assay, site-directed mutagenesis (C183A), apoptosis assay, NO scavenger rescue\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis identifies specific modification site with functional consequence; single lab\",\n      \"pmids\": [\"23657295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Naf1α (Nef-associated factor 1α) binds ERK2 directly (confirmed by yeast two-hybrid, pull-down, and immunoprecipitation); overexpression of Naf1α suppresses EGF-stimulated ERK2 nuclear translocation and inhibits ERK2-dependent Elk1-driven transcription, identifying Naf1α as an attenuator of nuclear ERK2 signaling.\",\n      \"method\": \"Yeast two-hybrid, in vitro pull-down, co-immunoprecipitation, GFP-ERK2 nuclear translocation assay, luciferase reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple binding assays plus functional nuclear translocation and reporter data; single lab\",\n      \"pmids\": [\"12220502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK2 specifically mediates metabolic stress-induced apoptosis via MEK1/ERK2 isoform-specific signaling; sustained low-glucose activates MEK1/ERK2, induces GCN2/eIF2α phosphorylation and ATF4 expression, and overrides PERK/Akt-mediated survival; supplementation with glutamate or α-ketoglutarate suppresses ERK2-dependent cell death.\",\n      \"method\": \"Isoform-specific siRNA knockdown, MEK inhibitors, metabolic flux analysis, apoptosis assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific knockdown with epistasis and metabolic readouts; single lab\",\n      \"pmids\": [\"26190261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ERK2 kinase drives a cancer drug addiction phenotype through a specific pathway: upon BRAF inhibitor withdrawal, ERK2-dependent transcriptional reprogramming (involving JUNB and FRA1) causes an epithelial-mesenchymal-like phenotype switch, MITF suppression, and cell death; CRISPR knockout of ERK2 (but not ERK1) allows addicted cells to survive drug discontinuation.\",\n      \"method\": \"CRISPR-Cas9 genome-wide screen, ERK2 isoform-specific knockout, gene expression profiling, xenograft models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased CRISPR screen with functional validation in vivo and mechanistic follow-up; strong study\",\n      \"pmids\": [\"28976960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK dimerization is essential for extranuclear (but not nuclear) ERK signaling; a small molecule inhibitor of ERK dimerization blocks tumorigenesis driven by RAS-ERK pathway oncogenes without affecting ERK phosphorylation, and is unaffected by known resistance mechanisms to BRAF/MEK inhibitors.\",\n      \"method\": \"Small molecule dimerization inhibitor, ERK dimerization mutagenesis, tumorigenesis assays, subcellular signaling readouts\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chemical and genetic disruption of dimerization with compartment-specific signaling readouts and in vivo validation\",\n      \"pmids\": [\"26267534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Small-angle X-ray scattering shows that the resting-state ERK2:HePTP complex adopts a highly extended, dynamic conformation, while the active-state complex becomes compact and ordered, demonstrating that ERK2-phosphatase complexes undergo significant conformational transitions related to regulation.\",\n      \"method\": \"Small-angle X-ray scattering combined with EROS ensemble refinement\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — structural characterization of resting vs. active complex; single lab, no mutagenesis validation\",\n      \"pmids\": [\"21985012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PLAC8 directly binds and inactivates the ERK2 phosphatase DUSP6 in vitro, thereby increasing phospho-ERK2 levels; ERK2 knockdown reverses PLAC8-induced EMT features (CDH1 reduction, CDH3/VIM/ZEB1 upregulation), placing elevated p-ERK2 downstream of PLAC8 in an unconventional EMT pathway in colon cancer.\",\n      \"method\": \"In vitro DUSP6 phosphatase activity assay with PLAC8, ERK2-specific shRNA knockdown, xenograft model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct in vitro enzyme inhibition assay plus isoform-specific knockdown and in vivo validation\",\n      \"pmids\": [\"24691442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PEA-15 sequesters ERK2 in the cytoplasm by binding via a reverse DEJL domain at its C-terminus; PEA-15 inhibits ERK2-mediated phosphorylations by blocking ERK2 interactions with DEJL domain-containing substrates/scaffolds, as demonstrated by competition with an Elk-1 DEJL peptide.\",\n      \"method\": \"Fluorescence anisotropy binding assays with purified proteins, competition experiments with peptides\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — quantitative in vitro binding analysis; functional implication of cytoplasmic sequestration mechanism\",\n      \"pmids\": [\"16324895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In Xenopus embryos, mechanical forces (centrifugal, compression, stretching) rapidly activate Erk2 in an FGFR1-dependent but FGF ligand-independent manner; activated Erk2 remodels cytoskeletal proteins (F-actin, C-cadherin, ZO-1) to enhance cellular junctions and stiffen embryonic tissue.\",\n      \"method\": \"Phosphoproteome analysis in Xenopus embryos, mechanical stimulation, FGFR1 inhibition, cytoskeletal imaging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphoproteomics plus inhibitor epistasis in Xenopus embryo model; ortholog with consistent function\",\n      \"pmids\": [\"32187556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERK2 (but not ERK1) is required for CD8 T cell proliferation in the absence of costimulation and enhances cell survival in the presence of costimulation by transcriptionally regulating Bcl-2 family members Bcl-xL and Bim; impaired Erk2-deficient CD8 T cell survival is rescued by genetic ablation of Bim.\",\n      \"method\": \"Conditional Erk2 gene targeting, Bim double-knockout rescue, FACS, BrdU proliferation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific genetic knockout with epistasis rescue in vivo\",\n      \"pmids\": [\"19017950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MEK1-ERK1/2 signaling in the heart is required for cardioprotection against ischemia-reperfusion injury; Erk2 heterozygous knockout mice show enhanced infarction, DNA laddering, and TUNEL compared to controls, while MEK1 transgenic mice with activated ERK1/2 are protected and preserve hemodynamic function.\",\n      \"method\": \"Erk2 heterozygous gene-targeted mice, MEK1 transgenic mice, ischemia-reperfusion model, TUNEL, pressure-volume loop recordings\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function and gain-of-function in vivo with defined mechanistic readouts\",\n      \"pmids\": [\"15096454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Expression of dominant-negative kinase-inactive ERK2 mutants in JB6 cells substantially inhibits tumor promoter-induced ERK1/2 and AP-1 activation and prevents neoplastic transformation, establishing ERK2 kinase activity as required for AP-1 transactivation and transformation.\",\n      \"method\": \"Dominant-negative ERK2 expression, AP-1/collagenase-luciferase reporter, transformation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative epistasis with functional transformation readout; single lab\",\n      \"pmids\": [\"10030673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERK2 morpholino knockdown in zebrafish blocks FGF-mediated dual-phosphorylated ERK2 at the blastula margin, preventing initiation of epiboly and reorganization of actin and tubulin cytoskeleton, arresting embryogenesis; ERK2 mRNA cross-rescues ERK1 knockdown but not vice versa, revealing distinct functions for ERK2 in cell migration during gastrulation.\",\n      \"method\": \"Morpholino knockdown, mRNA rescue, cell-tracing, F-actin/tubulin staining in zebrafish embryos\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — morpholino knockdown with isoform-specific mRNA rescue and cytoskeletal readouts in vivo\",\n      \"pmids\": [\"18514184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In Leishmania donovani, LdMAPK1 co-immunoprecipitates with and phosphorylates HSP70 and HSP90 foldosome complex subunits (HSP90, HSP70, STI, SGT), identified as the first substrates of LdMAPK1; MAPK1 abundance modulates HSP70/HSP90 expression.\",\n      \"method\": \"Co-immunoprecipitation, gel electrophoresis, mass spectrometry, western blot, in vitro kinase assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Symbol collision — Leishmania donovani LdMAPK1 is a distinct parasite protein, not an ortholog of human MAPK1/ERK2; excluded from main findings\",\n      \"pmids\": [\"28860596\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAPK1/ERK2 is a proline-directed serine/threonine kinase activated by dual phosphorylation (Thr and Tyr) by MEK1/2, which increases phosphoryl transfer rate ~60,000-fold; upon activation it undergoes global conformational changes enabling dimerization (via a defined dimer interface) and nuclear translocation (controlled by a cytoplasmic retention sequence involving residues 312–320 and a nuclear import sequence at 321–327), where it phosphorylates transcription factors (Elk1, Sp1, Beta2/NeuroD1, PDX-1, ETV3, C/EBPβ, NANOG) and nuclear partners (PARP-1); in the cytoplasm it phosphorylates substrates including PAK1-Thr212, RhoA (promoting SCF-FBXL19-mediated degradation), ULK1 (targeting it for proteasomal degradation to suppress mitophagy), and dynein (to regulate lipid droplet formation); its activity is negatively regulated by dual-specificity phosphatases (e.g., MKP3 via intramolecular dephosphorylation, HePTP) and by S-nitrosylation at Cys183; scaffold proteins (IQGAP1, MEKK1, PAK1, arrestin 2) control its spatial activation, while dimerization specifically enables extranuclear signaling that drives oncogenic RAS-ERK pathway tumorigenesis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"ERK2 (MAPK1) was cloned and identified as a protein-serine/threonine kinase activated by tyrosine phosphorylation in response to insulin and NGF, establishing it as an intermediate that converts tyrosine phosphorylation signals into serine/threonine phosphorylation cascades.\",\n      \"method\": \"Molecular cloning, biochemical kinase assays, phosphorylation analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning and biochemical characterization, foundational paper with 1747 citations\",\n      \"pmids\": [\"2032290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"ERK2 (42 kDa MAP kinase) is activated by phosphorylation on tyrosine and threonine downstream of oncogenic p21ras, and is constitutively activated in ras-transformed cell lines, placing ERK2 in the signal transduction pathway of the Ras oncoprotein.\",\n      \"method\": \"Scrape-loading of p21ras into cells, kinase activity assays, phosphorylation analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis/pathway placement with direct biochemical assays, highly cited foundational study\",\n      \"pmids\": [\"1371463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"cPLA2 is a direct substrate of MAP kinase (ERK); ERK phosphorylates cPLA2 at Ser-505, increasing its enzymatic activity, and mutation of Ser-505 to Ala abolishes agonist-stimulated arachidonate release.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, arachidonate release assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis confirming functional site\",\n      \"pmids\": [\"8381049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"MAP kinase (ERK, p42/p44) phosphorylates the Elk-1 C-terminal region at multiple sites both in vitro and in vivo following growth factor stimulation, and this phosphorylation is required for transcriptional activation by the serum response element.\",\n      \"method\": \"In vitro phosphorylation, co-immunoprecipitation, transcriptional reporter assays, phosphopeptide mapping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay combined with functional mutagenesis and reporter assays, 1219 citations\",\n      \"pmids\": [\"8386592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"MKP-1 (3CH134) is a dual-specificity phosphatase that dephosphorylates p42MAPK (ERK2) at both T183 and Y185 in vitro and inactivates it in vivo; a catalytically inactive MKP-1 mutant forms a physical complex with phosphorylated ERK2.\",\n      \"method\": \"In vitro phosphatase assay, co-immunoprecipitation, dominant-negative mutant expression\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis, replicated in vivo, 1086 citations\",\n      \"pmids\": [\"8221888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ERK MAP kinases phosphorylate Smad1 at specific serines in the linker region connecting its DNA-binding and effector domains, inhibiting nuclear accumulation of Smad1 and antagonizing BMP signaling.\",\n      \"method\": \"In vitro kinase assay, phosphopeptide mapping, nuclear localization assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation reconstitution with site identification, functional nuclear translocation assay\",\n      \"pmids\": [\"9335504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Mnk1 and Mnk2 bind directly to ERK1/2 (with Mnk1 complexing more strongly with inactive than active ERK), and ERK phosphorylates Mnk1/2 to stimulate their kinase activity toward eIF-4E at Ser209.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site mapping\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding and in vitro phosphorylation assays with functional downstream readout\",\n      \"pmids\": [\"9155017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MSK1 is directly activated by ERK2 (MAPK2/ERK2) in vitro, and endogenous MSK1 activation by growth factors is prevented by MEK inhibitor PD 98059; MSK1 phosphorylates CREB at Ser133, linking ERK2 signaling to CREB activation.\",\n      \"method\": \"In vitro kinase assay, pharmacological inhibition, CREB phosphorylation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of direct ERK2→MSK1 phosphorylation with functional downstream CREB readout\",\n      \"pmids\": [\"9687510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Phosphorylated ERK2 forms homodimers with both phosphorylated and unphosphorylated ERK2 partners; nuclear accumulation of ERK2 depends on its phosphorylation state and requires dimerization, as disruption of dimerization by mutagenesis reduces nuclear accumulation. Crystal structure of phosphorylated ERK2 reveals the structural basis for dimerization.\",\n      \"method\": \"Crystal structure determination, site-directed mutagenesis, microinjection, nuclear localization assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with mutagenesis and functional nuclear translocation assay\",\n      \"pmids\": [\"9604935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ERK2 residues 312–320 constitute a cytoplasmic retention sequence that mediates association with MEK1, retaining ERK2 in the cytosol; residues 316, 319, and 320 (acidic) are most critical. Residues 321–327 are required for nuclear translocation upon mitogenic stimulation.\",\n      \"method\": \"GFP-fusion protein expression, alanine-scanning mutagenesis, subcellular localization imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional mutagenesis identifying specific residues\",\n      \"pmids\": [\"10521408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ERK2 phosphorylates the transcription factor Sp1, and this phosphorylation stimulates Sp1 DNA binding; pretreatment with recombinant ERK2 increased Sp1 binding while dephosphorylation reduced it. Ras and ERK2 activation target the EGF-responsive gERE element via Sp1.\",\n      \"method\": \"In vitro phosphorylation assay, EMSA/DNA-binding assay, cotransfection reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro phosphorylation with functional DNA-binding readout; single lab\",\n      \"pmids\": [\"9918860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Activated ERK2 directly associates with and phosphorylates the docking protein GAB1; this association is exclusive to phosphorylated ERK2 and does not require a third protein. In intact cells, GAB1 co-immunoprecipitates with active ERK2.\",\n      \"method\": \"Pull-down assay with purified proteins, co-immunoprecipitation, in vitro kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted direct interaction with purified proteins and in vitro phosphorylation, confirmed in cells\",\n      \"pmids\": [\"10593929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ERK2 phosphorylates Smad2 and Smad3 at specific linker-region sites downstream of oncogenic Ras/ERK signaling, causing cytoplasmic retention and inhibiting TGF-β-induced nuclear accumulation and transcription. Ras-resistant Smad3 mutant rescues TGF-β growth inhibitory response.\",\n      \"method\": \"In vitro phosphorylation, site-directed mutagenesis, nuclear translocation assay, transcriptional reporter\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation, mutagenesis of specific sites, functional rescue, 843 citations\",\n      \"pmids\": [\"10197981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RKIP (Raf kinase inhibitor protein) binds to Raf-1, MEK, and ERK in vitro and co-immunoprecipitates with Raf-1 and MEK from cells, competitively disrupting Raf-1/MEK interaction and suppressing ERK activation. RKIP overexpression inhibits MEK, ERK, and AP-1 activation.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro binding, kinase activity assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal binding and functional assays across labs, 723 citations\",\n      \"pmids\": [\"10490027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MEKK1 binds directly to endogenous ERK2, MEK1, and Raf-1, suggesting it can scaffold all three components of the ERK2 MAP kinase module.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-immunoprecipitation of endogenous proteins, single lab\",\n      \"pmids\": [\"10969079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Dual phosphorylation of ERK2 at Thr-185 and Tyr-187 increases overall catalytic efficiency ~600,000-fold and turnover rate ~50,000-fold, primarily through a ~60,000-fold enhancement of the phosphoryl group transfer step, with only modest decreases in Km for ATP and substrate.\",\n      \"method\": \"In vitro kinase assay, solvent viscosimetry, steady-state kinetics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — detailed mechanistic in vitro kinetic analysis of catalytic mechanism\",\n      \"pmids\": [\"11016942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERK2 activation is required for glucose-stimulated insulin gene transcription; ERK2 phosphorylates transcription factors Beta2/NeuroD1 and PDX-1, increasing their functional activity and cumulatively transactivating the insulin promoter.\",\n      \"method\": \"Dominant-negative ERK2 expression, MEK inhibitors, in vitro phosphorylation, transcriptional reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative approach, pharmacological inhibition, and direct phosphorylation of substrates with functional readout\",\n      \"pmids\": [\"12810726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERK2 activation of the c-fos SRE through C/EBPbeta requires phosphorylation of a consensus MAPK site in C/EBPbeta; dominant-negative ERK2 (but not ERK1) blocks Ras-stimulated C/EBPbeta-SRF interaction, and recombinant ERK2 (but not ERK1) phosphorylates C/EBPbeta in vitro.\",\n      \"method\": \"Dominant-negative overexpression, in vitro kinase assay, co-immunoprecipitation, luciferase reporter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro phosphorylation with isoform selectivity and functional reporter assay; single lab\",\n      \"pmids\": [\"11500490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MUC1 cytoplasmic domain signaling leads to activation of ERK2 through the Ras-MEK-ERK2 pathway following tyrosine phosphorylation of MUC1; this was blocked by dominant-negative Ras or MEK inhibitor.\",\n      \"method\": \"Immunoblotting, kinase assay, immunocytochemistry, dominant-negative Ras, pharmacological inhibition\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional assays with pharmacological/genetic inhibition, single lab\",\n      \"pmids\": [\"11404250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Naf1α binds to ERK2 (confirmed by yeast two-hybrid, pull-down and co-immunoprecipitation); overexpression of Naf1α suppresses ERK2 nuclear translocation and inhibits ERK2-dependent Elk1-driven transcription, identifying Naf1α as an attenuator of activated ERK2 signaling.\",\n      \"method\": \"Yeast two-hybrid, pull-down assay, co-immunoprecipitation, nuclear translocation assay, luciferase reporter\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — multiple binding methods confirmed, functional consequence shown; single lab\",\n      \"pmids\": [\"12220502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MKP3 dephosphorylates ERK2 via an intramolecular mechanism: a 1:1 MKP3:pERK monomer complex forms, and MKP3 within this complex performs intramolecular dephosphorylation, achieving ≥4000-fold rate enhancement through catalytic activation and substrate tethering.\",\n      \"method\": \"In vitro phosphatase assay, chemical cross-linking, binding analyses, engineered mutants\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and cross-linking, mechanistic characterization of stoichiometry\",\n      \"pmids\": [\"14690430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IQGAP1 directly binds ERK2 (confirmed by in vitro pull-down with purified proteins and endogenous co-immunoprecipitation); manipulation of IQGAP1 levels significantly reduces growth factor-stimulated ERK1/2 activity, and an IQGAP1 construct lacking the ERK2-binding region does not interfere with ERK activation.\",\n      \"method\": \"In vitro pull-down with purified proteins, co-immunoprecipitation, siRNA knockdown, kinase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct protein-protein interaction reconstituted in vitro, confirmed in cells with functional consequence\",\n      \"pmids\": [\"14970219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERK2 phosphorylates PAK1 at Thr212 in vitro, and Thr212 is phosphorylated in smooth muscle cells after PDGF treatment in an MEK/ERK-dependent manner. PAK1 and ERK1/2 directly associate (Far Western analysis) at an ERK2 binding site within PAK1's autoinhibitory domain, and this association facilitates ERK signaling. A phosphomimic PAK1-T212E variant attenuates downstream ERK signaling, providing negative feedback.\",\n      \"method\": \"In vitro kinase assay, Far Western, co-immunoprecipitation, immunolocalization, luciferase reporter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding reconstituted, in vitro phosphorylation with site identification, functional consequence shown\",\n      \"pmids\": [\"15542607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Nonapoptotic programmed cell death mediated by the NK1R/Substance P pathway is executed through a MAPK cascade (Raf-1, MEK2, ERK2) recruited by arrestin 2 as scaffold, leading to phosphorylation of the orphan nuclear receptor Nur77. RNAi against ERK2 (but not ERK1) blocks this cell death.\",\n      \"method\": \"RNAi knockdown, dominant-negative constructs, pharmacological inhibition, cell death assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific RNAi with defined phenotypic readout and pathway placement; single lab\",\n      \"pmids\": [\"14769794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MEK1-ERK1/2 signaling is required for cardioprotection against ischemia-reperfusion injury; ERK2 heterozygous knockout mice show enhanced infarction, DNA laddering and TUNEL positivity, while MEK1 transgenic mice with activated ERK1/2 are resistant to injury.\",\n      \"method\": \"Gene-targeted knockout mice, transgenic overexpression, ischemia-reperfusion in vivo model, pressure-volume loop recordings, TUNEL assay\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function and gain-of-function in vivo with defined cardiac phenotype\",\n      \"pmids\": [\"15096454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Noonan syndrome PTPN11/SHP2 mutants cause prolonged ERK2/MAPK1 activation in a ligand- and GAB1-docking-dependent manner; coexpression of GAB1-FF (lacking SHP2 binding motifs) blocks EGF-mediated increase in SHP2 phosphatase activity and reduces ERK2 activation.\",\n      \"method\": \"Kinase activity assays, co-immunoprecipitation, dominant-negative/mutant overexpression, proliferation assays\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional pathway analysis with mutant proteins; single lab\",\n      \"pmids\": [\"14974085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK2 uses a proximity-mediated catalysis mechanism: docking of a substrate recognition domain (pnt domain of EtsDelta138) outside the active site increases local concentration of the phosphoacceptor TP motif near the catalytic site; mutagenesis of the pnt domain reduces binding 10-fold but kcat is unchanged, while mutagenesis of the TP motif decreases kcat without affecting ternary complex stability.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, binding studies\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic reconstitution with systematic mutagenesis of both enzyme and substrate\",\n      \"pmids\": [\"16045329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FR180204, an ERK-selective ATP-competitive inhibitor (Ki 0.14 µM for ERK2), binds within the ATP-binding pocket of ERK2 engaging residues Q105, D106, L156, and C166, as determined by X-ray crystallography of the human ERK2/FR180204 complex.\",\n      \"method\": \"X-ray crystallography, enzyme kinetic assay (Lineweaver-Burk), cell-based reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with biochemical validation\",\n      \"pmids\": [\"16139248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PEA-15 sequesters ERK2 in the cytoplasm by binding to ERK2 through a reverse DEJL domain in its C-terminus, thereby blocking ERK2 interactions with DEJL-containing substrates and inhibiting many ERK2-mediated phosphorylations.\",\n      \"method\": \"Fluorescence anisotropy binding assay, peptide displacement studies\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative binding data with mechanistic model; single lab\",\n      \"pmids\": [\"16324895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK2 is required for cardioprotection, T cell development, positive selection, and CD4/CD8 T cell maturation; conditional and global knockout studies demonstrate ERK2's predominant in vivo roles compared to ERK1.\",\n      \"method\": \"Gene-targeted knockout mice, T cell development analysis, proliferation and survival assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function in vivo with defined cellular phenotypes at multiple developmental stages\",\n      \"pmids\": [\"16226508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK MAP kinase phosphorylates TSC2 at specific Erk sites, causing dissociation of the TSC1-TSC2 complex and markedly impairing TSC2's ability to inhibit mTOR signaling and cell transformation; an Erk-nonphosphorylatable TSC2 mutant blocks tumorigenicity in vivo.\",\n      \"method\": \"In vitro phosphorylation, co-immunoprecipitation, mutagenesis, xenograft tumor model\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation with mutant rescue in vivo, 1067 citations\",\n      \"pmids\": [\"15851026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ERK2 (but not ERK1, JNK, or p38) plays a specific role in cytosolic lipid droplet formation; ERK2 phosphorylates dynein, increasing its localization on ADRP-containing lipid droplets. ERK2 functions downstream of PLD1 in this process, without affecting PLD1 activity.\",\n      \"method\": \"siRNA knockdown, microinjection, overexpression, phosphorylation assay, lipid droplet quantification\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific knockdown and overexpression with mechanistic substrate identification; single lab\",\n      \"pmids\": [\"16723731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Phosphorylated ERK2 directly interacts with and activates PARP-1 in a DNA-independent manner in a cell-free system; activated PARP-1 dramatically increases ERK2-catalyzed phosphorylation of Elk1. In cortical neurons and cardiomyocytes, PARP-1 activation enhances ERK-induced Elk1 phosphorylation, histone acetylation, and c-fos transcription.\",\n      \"method\": \"Cell-free reconstitution, co-immunoprecipitation, kinase assay, reporter gene assay, primary cell experiments\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cell-free reconstitution of direct interaction with functional consequence, validated in primary cells\",\n      \"pmids\": [\"17244536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ERK2 activation in platelets requires simultaneous signaling from both P2Y1 (Gq-coupled) and P2Y12 (Gi-coupled) ADP receptors plus Src kinase activity; ERK2 activation is required for ADP-induced thromboxane A2 generation, and extracellular calcium blocks ADP-induced ERK2 activation.\",\n      \"method\": \"Pharmacological inhibition of specific receptors/kinases, kinase activity assay, thromboxane measurement\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined pathway placement with multiple pharmacological tools and functional output; single lab\",\n      \"pmids\": [\"17298299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mitochondrially localized ERK2 activity is sufficient to induce mitophagy; active ERK2-CA shows greater localization to mitochondria than WT, and kinase activity (not just localization) correlates with degree of mitophagy. ERK2 localization to mitochondria is triggered by 6-OHDA.\",\n      \"method\": \"GFP-ERK2 fusion constructs (WT, CA, KD), colocalization imaging, autophagy marker analysis (LC3), bafilomycin treatment\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with kinase-dead controls establishing activity-dependent mitophagy; single lab\",\n      \"pmids\": [\"18594198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERK2 (but not ERK1) is required for proliferation of CD8 T cells activated without costimulation, and regulates CD8 T cell survival by transcriptionally upregulating Bcl-xL and downregulating Bim; impaired ERK2-deficient CD8 T cell survival can be rescued by genetic ablation of Bim.\",\n      \"method\": \"Conditional Erk2 knockout, viral infection model, in vitro activation, Bim genetic rescue\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with mechanistic rescue, isoform-specific role defined\",\n      \"pmids\": [\"19017950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERK2 morpholino knockdown in zebrafish blocks initiation of epiboly, actin/tubulin cytoskeleton reorganization, and causes severe anterior-posterior extension defects; ERK2 mRNA cross-rescues ERK1 morphants, but ERK1 mRNA cannot rescue ERK2 morphants, suggesting distinct functions.\",\n      \"method\": \"Morpholino knockdown, mRNA rescue, cell-tracing, cytoskeleton imaging in zebrafish embryos\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — morpholino knockdown with cross-rescue in vertebrate model organism; single lab\",\n      \"pmids\": [\"18514184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Large-scale chemical-genetic screen using analog-sensitive ERK2 identified 80 ERK2 substrates; ETV3 is a novel substrate extensively phosphorylated at canonical and noncanonical ERK motifs, and this phosphorylation prevents ETV3 binding to DNA at promoters of thousands of genes including negative feedback regulators.\",\n      \"method\": \"Analog-sensitive kinase assay (chemical genetics), mass spectrometry, ChIP-seq, reporter assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro substrate identification with functional validation of novel substrate ETV3\",\n      \"pmids\": [\"22028470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The ERK2:HePTP complex transitions from a highly extended dynamic resting-state conformation to a compact, ordered active-state conformation as determined by SAXS combined with EROS ensemble refinement; HePTP negatively regulates ERK2 via dephosphorylation.\",\n      \"method\": \"Small-angle X-ray scattering (SAXS), EROS ensemble refinement\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — solution structural determination with functional context; single lab\",\n      \"pmids\": [\"21985012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ERK1/2-dependent phosphorylation of PKM2 at Ser37 (by ERK2 binding directly to PKM2 Ile429/Leu431 through the ERK2 docking groove) recruits PIN1 for cis-trans isomerization, promotes PKM2 nuclear translocation, and nuclear PKM2 acts as β-catenin coactivator to induce c-Myc and the Warburg effect.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, mutagenesis, nuclear fractionation, xenograft tumor model\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct ERK2-PKM2 interaction characterized at residue level, in vitro phosphorylation, in vivo functional consequence, 769 citations\",\n      \"pmids\": [\"23178880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERK2-mediated phosphorylation of RhoA is required for SCF(FBXL19)-mediated RhoA ubiquitination at Lys135 and proteasomal degradation; RhoA-K135R mutant is resistant to FBXL19-mediated ubiquitination. ERK2 phosphorylation of RhoA is both sufficient and required for this degradation.\",\n      \"method\": \"In vitro kinase assay, ubiquitination assay, mutagenesis, co-immunoprecipitation, protein stability assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation required for ubiquitination reconstituted, with mutagenesis confirmation\",\n      \"pmids\": [\"23871831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PLAC8 directly binds and inactivates the ERK2 phosphatase DUSP6 in vitro, thereby increasing phospho-ERK2 levels and driving an unconventional EMT in colon cancer characterized by increased VIM, ZEB1, and CDH3 without CDH2 upregulation; ERK2 knockdown reverses these EMT features.\",\n      \"method\": \"In vitro protein binding assay, ERK2 knockdown, immunofluorescence, xenograft model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical interaction of PLAC8 with DUSP6 in vitro, ERK2 KD with functional rescue, confirmed in vivo\",\n      \"pmids\": [\"24691442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Dual phosphorylation of ERK2 by MAP kinase kinase 1 induces global conformational exchange dynamics (two-state exchange, kex ≈ 300 s⁻¹) throughout the conserved kinase core, releasing constraints on domain motions; inactive ERK2 shows only localized, uncoupled side-chain dynamics.\",\n      \"method\": \"NMR 13C relaxation dispersion experiments (side-chain methyl dynamics), phosphorylation by MKK1\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural dynamics with functional validation via phosphorylation-induced changes\",\n      \"pmids\": [\"24550275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ERK2 directly phosphorylates NANOG at multiple sites in vitro; using the MAKS multiplexed kinase assay, ERK2 and CDK1/CyclinA2 were identified as site-specific kinases for human NANOG, linking key signaling pathways to pluripotency regulation.\",\n      \"method\": \"MAKS (multiplexed assay for kinase specificity), mass spectrometry phosphopeptide mapping\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro direct phosphorylation with site identification; single lab, no in vivo functional rescue\",\n      \"pmids\": [\"24678451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK2 dimerization is essential for extranuclear (but not nuclear) ERK signaling; a small molecule inhibitor of ERK dimerization prevents RAS-ERK oncogene-driven tumorigenesis without affecting ERK phosphorylation, demonstrating that dimerization controls sub-localization-specific ERK signaling.\",\n      \"method\": \"Small molecule inhibitor design, dimerization assays, cancer cell transformation assays, mouse tumor models\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological disruption of dimerization with in vivo functional consequence, mechanistic dissection of nuclear vs extranuclear signaling\",\n      \"pmids\": [\"26267534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of ERK2 in complex with RSK1 reveals a precatalytic kinase-kinase heterodimer where the RSK1 activation loop faces ERK2's catalytic site; the MAPK-binding linear motif in RSK1's disordered kinase domain extension docks into ERK2's groove to form the encounter complex, and generic kinase domain surface contacts enable the catalytically competent state.\",\n      \"method\": \"X-ray crystallography, molecular dynamics simulation, biochemical and cellular kinase assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with MD simulation and biochemical validation\",\n      \"pmids\": [\"25730857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Under low-glucose metabolic stress, isoform-specific MEK1/ERK2 signaling (not ERK1) activates GCN2/eIF2α phosphorylation and ATF4 expression, which overrides PERK/Akt-mediated adaptation and induces apoptosis through ATF4-dependent pro-apoptotic factor expression including Bid and Trb3. ERK2 activation also alters TCA cycle and amino acid metabolism.\",\n      \"method\": \"Isoform-specific knockdown/overexpression, phosphoproteomics, metabolomics, apoptosis assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific manipulation with mechanistic pathway placement and metabolic readouts; multiple methods\",\n      \"pmids\": [\"26190261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Akt, Erk2, and IKK1/2 phosphorylate Bcl3 at distinct sites: Erk2 and IKK1/2 phosphorylate Ser114 and Ser446, converting Bcl3 from an IκB-like inhibitor to a transcriptional coregulator by facilitating its recruitment to DNA. Cells expressing S114A/S446A Bcl3 have proliferation and migration defects.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, ChIP, cell proliferation and migration assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro direct phosphorylation with mutagenesis and functional consequences in cells\",\n      \"pmids\": [\"28689659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In BRAF-inhibitor-resistant melanoma, ERK2 kinase drives a phenotype switch (resembling EMT with MITF shutdown) upon drug withdrawal, through a pathway involving ERK2, JUNB, and FRA1 transcription factors; CRISPR-Cas9 screen identified this as the core 'drug addiction' pathway.\",\n      \"method\": \"Unbiased CRISPR-Cas9 knockout screen, transcriptomics, mouse tumor models, patient sample analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide unbiased screen with in vivo validation and patient sample confirmation\",\n      \"pmids\": [\"28976960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK inhibitors Vertex-11e and SCH772984 exploit conformational equilibrium in active 2P-ERK2 by shifting exchange between two states (L and R) in opposing directions; X-ray structures and NMR/HX-MS measurements show that the L→R shift in 2P-ERK2 involves active site domain closure for productive nucleotide binding, and these inhibitors differentially affect MAP kinase phosphatase activity toward 2P-ERK2.\",\n      \"method\": \"NMR, X-ray crystallography, hydrogen-exchange mass spectrometry, phosphatase activity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures combined with NMR and HX-MS and functional phosphatase assays\",\n      \"pmids\": [\"31311868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MAPK1/ERK2-MAPK3/ERK1 kinase phosphorylates ULK1, triggering ULK1 interaction with BTRC and subsequent K48-linked ubiquitination and proteasomal degradation. ULK1 depletion attenuates mitophagy during hypoxia, causing accumulation of ROS-generating mitochondria and NLRP3 inflammasome activation that promotes breast cancer bone metastasis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, ubiquitination assay, MEK inhibitor (trametinib), xenograft model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct phosphorylation of ULK1 by ERK, ubiquitination mechanism defined, functional in vivo consequence\",\n      \"pmids\": [\"33213267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mechanical force (centrifugal, compression, stretching) rapidly activates Erk2 in Xenopus embryos in an FGFR1-dependent but FGF-ligand-independent manner; Erk2 activation induces cytoskeletal remodeling (F-actin, C-cadherin, ZO-1), enhancing cellular junctions and tissue stiffening during early embryogenesis.\",\n      \"method\": \"Phosphoproteome analysis of Xenopus embryos, force application experiments, FGFR1 inhibition, cytoskeletal protein analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphoproteomics in intact embryo model with pharmacological intervention; single lab\",\n      \"pmids\": [\"32187556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MAPK1 binds directly to promoter regions of target genes as a bidirectional transcription factor in gastric cancer cells; ChIP-seq and biochemical assays demonstrate MAPK1 upregulates KRT13, KRT6A, KRT81, MYH15, STARD4, SYTL4, TMEM267 and downregulates FGG, promoting cell invasion and migration.\",\n      \"method\": \"ChIP-seq, ChIP assay, RNA sequencing, protein interaction assays, cell migration/invasion assays\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq with functional cellular assays; single lab, novel transcription factor role\",\n      \"pmids\": [\"37817112\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAPK1/ERK2 is a dual-specificity-activated serine/threonine kinase that, upon dual phosphorylation at Thr185/Tyr187 by MEK1/2 (causing a ~600,000-fold increase in catalytic efficiency and global conformational exchange enabling active-site closure), dimerizes and translocates to the nucleus where it phosphorylates transcription factors (Elk-1, Sp1, C/EBPβ, ETV3, NANOG, Beta2/PDX-1), and in the cytoplasm phosphorylates diverse substrates (cPLA2, Smad1/2/3, TSC2, PKM2, RhoA, ULK1, PAK1, Bcl3, dynein) to regulate proliferation, survival, differentiation, motility, metabolism, autophagy/mitophagy, and gene expression; its activity is spatially controlled by scaffold proteins (β-arrestin, IQGAP1, MEKK1), cytoplasmic retention via MEK1 binding to residues 312–320, inhibitory binding partners (PEA-15, Naf1α), and inactivation by dual-specificity phosphatases (MKP-1, MKP3/DUSP6, HePTP), while ERK2 dimerization specifically governs extranuclear signaling and can also function as a direct transcription factor binding to gene promoters.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MAPK1/ERK2 is a proline-directed serine/threonine kinase that serves as a central node in the RAS-RAF-MEK signaling cascade, transducing extracellular signals into diverse cellular responses including proliferation, differentiation, survival, and cytoskeletal remodeling. Dual phosphorylation on threonine and tyrosine by MEK1/2 increases ERK2 catalytic efficiency approximately 600,000-fold and induces global conformational dynamics that enable homodimerization and nuclear translocation, with dimerization specifically required for extranuclear signaling and oncogenic tumorigenesis [PMID:11016942, PMID:24550275, PMID:9604935, PMID:26267534]. In the nucleus, ERK2 phosphorylates transcription factors including Elk1, Sp1, C/EBPβ, Beta2/NeuroD1, ETV3, and NANOG, and activates PARP-1 to promote gene expression programs; in the cytoplasm, it phosphorylates substrates such as PAK1, RhoA, ULK1, and dynein to regulate feedback signaling, proteasomal degradation, mitophagy, and lipid droplet biogenesis [PMID:17244536, PMID:22028470, PMID:11500490, PMID:33213267, PMID:16723731]. ERK2 activity is spatially controlled by scaffold proteins (IQGAP1, arrestin 2, PEA-15), negatively regulated by dual-specificity phosphatases such as MKP3 via intramolecular dephosphorylation, and inhibited by S-nitrosylation at Cys183 [PMID:14690430, PMID:14970219, PMID:23657295, PMID:16324895].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing that ERK2 operates downstream of Ras resolved a key gap in receptor-to-kinase signal transmission, positioning ERK2 as a major effector of oncogenic and growth factor signaling.\",\n      \"evidence\": \"Scrape-loading of oncogenic p21ras into quiescent cells activated ERK2 kinase activity with dual Thr/Tyr phosphorylation, independent of growth factors\",\n      \"pmids\": [\"1371463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the intermediate kinase(s) between Ras and ERK2 not yet defined\", \"Whether ERK2 and ERK1 have distinct roles downstream of Ras was unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Determining that phosphorylated ERK2 dimerizes and that dimerization is required for nuclear translocation explained how activation is coupled to subcellular redistribution.\",\n      \"evidence\": \"Crystal structure of phosphorylated ERK2 revealed the dimer interface; mutagenesis of the interface blocked nuclear accumulation upon microinjection\",\n      \"pmids\": [\"9604935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dimerization serves functions beyond nuclear entry was unknown\", \"The nuclear import receptor engaged by ERK2 dimers was not identified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mapping a cytoplasmic retention sequence (residues 312–320) and a nuclear import sequence (321–327) in ERK2 defined the cis-elements governing MEK-dependent cytoplasmic anchoring versus mitogen-stimulated nuclear entry.\",\n      \"evidence\": \"Alanine-scanning mutagenesis of GFP-ERK2 in CHO cells with live-cell imaging and MEK1 co-expression\",\n      \"pmids\": [\"10521408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors recognizing these sequences were not identified\", \"Regulation of this switch beyond MEK-dependent phosphorylation was unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Quantifying the catalytic consequences of dual phosphorylation — a ~60,000-fold increase in phosphoryl transfer rate — revealed that activation primarily accelerates chemistry rather than substrate binding.\",\n      \"evidence\": \"In vitro kinase assays with solvent viscosometric analysis comparing unphosphorylated and phosphorylated ERK2\",\n      \"pmids\": [\"11016942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the conformational change mechanistically accelerates the chemical step was structurally unresolved\", \"Whether this magnitude applies to all substrates was untested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating ERK2-isoform-specific phosphorylation of C/EBPβ and regulation of the serum response element revealed that ERK1 and ERK2 have non-redundant transcription factor substrates.\",\n      \"evidence\": \"In vitro kinase assays showed ERK2 but not ERK1 phosphorylates C/EBPβ; dominant-negative ERK2 but not ERK1 blocked C/EBPβ-SRF interaction\",\n      \"pmids\": [\"11500490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for ERK2 selectivity over ERK1 for C/EBPβ was undefined\", \"Whether this selectivity extends to other C/EBP family members was unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Elucidating the intramolecular dephosphorylation mechanism of MKP3 — forming a 1:1 heterodimer with pERK2 for a ≥4000-fold rate enhancement — defined how dual-specificity phosphatases achieve efficient ERK2 inactivation.\",\n      \"evidence\": \"Kinetic analysis, chemical cross-linking, and mutagenesis of MKP3 and ERK2 in vitro\",\n      \"pmids\": [\"14690430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same mechanism applies to other DUSPs was not tested\", \"Structural details of the MKP3:ERK2 heterodimer were lacking\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of IQGAP1 as a direct ERK2-binding scaffold and of arrestin 2 as a recruiter of the MEK2–ERK2 module established that spatial organization of ERK2 signaling depends on specific scaffold proteins.\",\n      \"evidence\": \"In vitro pull-down and endogenous co-IP for IQGAP1; dominant-negative arrestin 2 and isoform-specific RNAi for the arrestin 2–MEK2–ERK2 pathway in primary neurons\",\n      \"pmids\": [\"14970219\", \"14769794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How scaffold occupancy selects specific ERK2 substrates was mechanistically unclear\", \"Whether IQGAP1 and arrestin 2 compete for ERK2 binding was not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that ERK2 uses docking-domain-mediated proximity to phosphorylate Ets substrates distinguished the catalytic mechanism from simple active-site encounter and explained substrate selectivity.\",\n      \"evidence\": \"In vitro kinase assays with mutant EtsDelta138 substrates showed docking affects Km without affecting kcat, while active-site mutations affect kcat without disrupting binding\",\n      \"pmids\": [\"16045329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all ERK2 substrates rely on DEJL/DEF docking motifs was unresolved\", \"Structural visualization of a docked substrate–ERK2 complex was lacking at this point\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying ERK2 as specifically required for lipid droplet formation — acting through dynein phosphorylation downstream of PLD1 — extended ERK2 function beyond canonical nuclear signaling to cytoplasmic organelle biogenesis.\",\n      \"evidence\": \"Isoform-specific siRNA plus cell-free lipid droplet reconstitution assay; dynein identified as ERK2 substrate by kinase assay\",\n      \"pmids\": [\"16723731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific dynein phosphorylation site(s) were not mapped\", \"Whether ERK2-dynein interaction is direct or scaffold-mediated was unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing that phosphorylated ERK2 directly activates PARP-1 in a DNA-damage-independent manner, which in turn enhances ERK2-mediated Elk1 phosphorylation, revealed a feed-forward nuclear amplification loop linking ERK2 to chromatin modification.\",\n      \"evidence\": \"Cell-free reconstitution with recombinant proteins, co-IP, kinase assay, and c-fos reporter in primary neurons and cardiomyocytes\",\n      \"pmids\": [\"17244536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The PARP-1 domain responsible for ERK2 binding was not mapped\", \"Whether poly(ADP-ribosyl)ation of chromatin is required for the feed-forward effect was untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"A chemical-genetic screen identifying 80 direct ERK2 substrates, including ETV3, massively expanded the known substrate repertoire and showed ERK2 phosphorylation prevents ETV3 DNA binding at thousands of promoters.\",\n      \"evidence\": \"Analog-sensitive ERK2 with ATP analog labeling, mass spectrometry, ChIP-seq, and transcriptional reporters\",\n      \"pmids\": [\"22028470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which of the 80 substrates are physiologically relevant in vivo was largely unvalidated\", \"Whether ETV3 regulation is ERK2-isoform-specific was not determined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovering that S-nitrosylation at Cys183 inhibits ERK2 phosphorylation and promotes apoptosis identified a redox-based post-translational switch that directly antagonizes the canonical activation mechanism.\",\n      \"evidence\": \"S-nitrosylation assay and C183A mutagenesis with apoptosis readouts\",\n      \"pmids\": [\"23657295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether S-nitrosylation occurs at physiological NO concentrations in specific tissues was not established\", \"The structural mechanism by which Cys183 modification blocks Thr/Tyr phosphorylation was not determined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"NMR relaxation dispersion revealed that MEK-mediated phosphorylation shifts ERK2 from localized side-chain motions to a global two-state domain motion, providing a biophysical basis for how phosphorylation unlocks the kinase core.\",\n      \"evidence\": \"13C methyl relaxation dispersion NMR with hinge-region mutagenesis on recombinant ERK2\",\n      \"pmids\": [\"24550275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the two-state conformational equilibrium relates to substrate selectivity was unknown\", \"Whether this dynamic mechanism is shared by ERK1 was not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that ERK dimerization is specifically required for extranuclear but not nuclear signaling, and that a dimerization inhibitor blocks RAS-ERK-driven tumorigenesis, separated nuclear and cytoplasmic ERK2 functions and identified a new therapeutic vulnerability.\",\n      \"evidence\": \"Small-molecule ERK dimerization inhibitor and dimerization-defective mutants tested for compartment-specific signaling and tumorigenesis in vivo\",\n      \"pmids\": [\"26267534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The identity of the critical extranuclear substrates requiring dimeric ERK2 was not fully resolved\", \"Whether the dimerization inhibitor has off-target effects on other MAPK family members was not excluded\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The crystal structure of the ERK2–RSK1 heterodimer captured a precatalytic state, showing how the docking groove interaction evolves into a catalytically competent kinase–substrate complex.\",\n      \"evidence\": \"X-ray crystallography with MD simulation and biochemical binding assays\",\n      \"pmids\": [\"25730857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the precatalytic-to-catalytic transition involves conformational intermediates was not resolved\", \"Generalizability to other ERK2 substrates beyond RSK1 was not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A genome-wide CRISPR screen showed that ERK2 knockout (but not ERK1) allows BRAF-inhibitor-addicted melanoma cells to survive drug withdrawal, revealing ERK2 as the isoform driving drug-addiction-associated transcriptional reprogramming and cell death.\",\n      \"evidence\": \"CRISPR-Cas9 screen, ERK2-specific knockout, gene expression profiling, xenograft validation\",\n      \"pmids\": [\"28976960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The direct ERK2 substrates mediating the JUNB/FRA1 transcriptional switch were not identified\", \"Whether this isoform specificity applies across cancer types was untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ERK1/2 phosphorylation of ULK1 triggers BTRC-mediated K48-ubiquitination and proteasomal degradation of ULK1, establishing a direct mechanism by which the RAS-ERK pathway suppresses mitophagy.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, ubiquitination assay, trametinib rescue, shRNA knockdown\",\n      \"pmids\": [\"33213267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific ULK1 phosphorylation sites targeted by ERK2 were not fully mapped\", \"Whether ERK2 preferentially over ERK1 controls ULK1 degradation was not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the full inventory of ERK2-isoform-specific substrates in vivo, the structural basis for ERK1/ERK2 substrate discrimination, and the physiological contexts in which S-nitrosylation versus dual phosphorylation predominate.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No systematic in vivo phosphoproteomics comparing ERK1 and ERK2 knockout tissues\", \"No crystal structure of S-nitrosylated ERK2\", \"How scaffold proteins partition ERK2 between nuclear and cytoplasmic substrate pools remains mechanistically undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 5, 7, 10, 11, 13, 14, 16, 21, 22, 23, 24]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 7, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 3, 5, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 15, 34]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [18, 19]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3, 6, 8, 12, 31]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [27, 29, 36, 37]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [18, 19, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 7, 10, 11, 21, 30]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [36, 38]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [39]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [36]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [20, 22]}\n    ],\n    \"complexes\": [\n      \"ERK2 homodimer\",\n      \"ERK2-RSK1 heterodimer\",\n      \"ERK2-HePTP complex\",\n      \"Arrestin 2-Raf1-MEK2-ERK2 signalosome\"\n    ],\n    \"partners\": [\n      \"IQGAP1\",\n      \"PARP1\",\n      \"MAP2K1\",\n      \"PEA15\",\n      \"GAB1\",\n      \"PAK1\",\n      \"RPS6KA1\",\n      \"PTPN7\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MAPK1/ERK2 is a central serine/threonine kinase in the Ras–Raf–MEK–ERK signaling cascade that transduces mitogenic, stress, and mechanical stimuli into phosphorylation of a broad substrate repertoire controlling proliferation, differentiation, survival, metabolism, cytoskeletal dynamics, and autophagy. Dual phosphorylation at Thr185/Tyr187 by MEK1/2 increases catalytic efficiency approximately 600,000-fold by inducing global conformational exchange dynamics that enable active-site domain closure, and promotes ERK2 homodimerization required for extranuclear signaling and nuclear translocation [PMID:11016942, PMID:24550275, PMID:9604935, PMID:26267534]. In the nucleus, ERK2 phosphorylates transcription factors including Elk-1, Sp1, C/EBPβ, ETV3, NANOG, and Beta2/PDX-1, and can also bind gene promoters directly as a transcription factor; in the cytoplasm, it phosphorylates cPLA2, Smad1/2/3, TSC2, PKM2, RhoA, ULK1, PAK1, Bcl3, and dynein, linking ERK2 to arachidonate release, TGF-β/BMP antagonism, mTOR activation, the Warburg effect, protein turnover, mitophagy, and lipid droplet biogenesis [PMID:8381049, PMID:15851026, PMID:23178880, PMID:33213267, PMID:37817112]. ERK2 activity is spatially controlled by cytoplasmic retention through MEK1 binding (residues 312–320) and inhibitory partners PEA-15 and Naf1α, and temporally controlled by dual-specificity phosphatases MKP-1, MKP3/DUSP6, and HePTP, while scaffold proteins β-arrestin/arrestin-2 and IQGAP1 direct pathway-specific signaling outputs [PMID:10521408, PMID:8221888, PMID:14690430, PMID:14970219, PMID:14769794].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Cloning of ERK2 established the founding paradigm of a protein-serine/threonine kinase activated by tyrosine phosphorylation, answering how growth factor and insulin receptor tyrosine kinase signals are converted into serine/threonine phosphorylation cascades.\",\n      \"evidence\": \"Molecular cloning and biochemical kinase assays in insulin/NGF-stimulated cells\",\n      \"pmids\": [\"2032290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream activating kinase not yet identified\", \"No substrates known at this stage\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Positioning ERK2 downstream of oncogenic Ras resolved a critical gap in the Ras signaling pathway and explained how Ras transduces signals through cytoplasmic kinase cascades.\",\n      \"evidence\": \"Scrape-loading of p21ras into cells with ERK2 activity measurement; constitutive activation in Ras-transformed lines\",\n      \"pmids\": [\"1371463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct intermediary kinases between Ras and ERK2 not defined\", \"Mechanism of ERK2 activation (dual phosphorylation requirement) not yet established\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of cPLA2 and Elk-1 as direct ERK substrates answered what ERK2 phosphorylates, connecting the kinase to both lipid signaling (arachidonate release) and transcriptional activation (serum response element), and establishing the MAPK proline-directed phosphorylation motif.\",\n      \"evidence\": \"In vitro kinase assays with site-directed mutagenesis (cPLA2 Ser505; Elk-1 C-terminal domain) and functional readouts\",\n      \"pmids\": [\"8381049\", \"8386592\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ERK2 selects among multiple substrates unknown\", \"Nuclear versus cytoplasmic substrate targeting mechanisms unresolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Discovery that MKP-1 dephosphorylates both pThr and pTyr on ERK2 established the first negative-feedback mechanism for pathway termination, resolving how ERK2 is inactivated.\",\n      \"evidence\": \"In vitro phosphatase assay with catalytically inactive MKP-1 trapping phospho-ERK2 complex\",\n      \"pmids\": [\"8221888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of different phosphatases in different cell contexts unknown\", \"Spatial control of dephosphorylation not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of Smad1 and Mnk1/2 as ERK2 substrates expanded the functional scope, showing ERK2 antagonizes BMP signaling by blocking Smad nuclear entry and controls translation initiation through Mnk-eIF4E phosphorylation.\",\n      \"evidence\": \"In vitro phosphorylation with site mapping and nuclear localization assays (Smad1); co-IP and kinase assays (Mnk1/2)\",\n      \"pmids\": [\"9335504\", \"9155017\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERK2 regulates all TGF-β superfamily Smads unknown\", \"In vivo significance of Mnk pathway for translation control not tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Crystal structure of phosphorylated ERK2 revealed the structural basis for dimerization and linked dimerization to nuclear accumulation, answering how activation-state controls subcellular distribution.\",\n      \"evidence\": \"X-ray crystallography combined with mutagenesis disrupting the dimer interface and microinjection nuclear translocation assays\",\n      \"pmids\": [\"9604935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dimerization is required for all nuclear functions unknown\", \"Mechanism of nuclear import (importin involvement) not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mapping of ERK2 residues 312–320 as a MEK1-dependent cytoplasmic retention signal and residues 321–327 as a nuclear translocation element resolved the molecular mechanism of ERK2 shuttling between nucleus and cytoplasm.\",\n      \"evidence\": \"GFP-fusion alanine-scanning mutagenesis with subcellular localization imaging\",\n      \"pmids\": [\"10521408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of nuclear import receptors interacting with residues 321–327 not determined\", \"How phosphorylation releases the MEK1 anchor quantitatively not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that ERK2 phosphorylates Smad2/3 linker regions causing their cytoplasmic retention explained how oncogenic Ras signaling overrides TGF-β growth inhibition, a mechanism directly relevant to cancer biology.\",\n      \"evidence\": \"In vitro phosphorylation, mutagenesis, nuclear translocation and transcriptional reporter assays; Ras-resistant Smad3 mutant rescue\",\n      \"pmids\": [\"10197981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mechanism operates in all Ras-driven cancers not established\", \"Phosphatase that reverses ERK-mediated Smad phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Quantitative kinetic analysis showed dual phosphorylation increases ERK2 catalytic efficiency ~600,000-fold, primarily through enhancement of the phosphoryl transfer step, answering why dual (not single) phosphorylation is required for full activation.\",\n      \"evidence\": \"Steady-state kinetics and solvent viscosimetry with purified mono- and dually-phosphorylated ERK2\",\n      \"pmids\": [\"11016942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for the rate enhancement at the phosphoryl transfer step not resolved at atomic level\", \"Contribution of each phosphosite individually not fully dissected\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mechanistic dissection of MKP3/DUSP6 revealed an intramolecular dephosphorylation mechanism within a 1:1 MKP3:pERK2 complex achieving >4000-fold rate enhancement, explaining the exquisite specificity and efficiency of ERK2 inactivation.\",\n      \"evidence\": \"In vitro phosphatase assay with chemical cross-linking, binding analyses, and engineered mutants\",\n      \"pmids\": [\"14690430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this intramolecular mechanism applies to all DUSPs unknown\", \"Structural basis of catalytic activation within the complex not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"In vivo genetic studies established ERK2 as the predominant isoform for cardioprotection against ischemia-reperfusion injury and for T cell development/positive selection, answering whether ERK1 and ERK2 are functionally redundant.\",\n      \"evidence\": \"ERK2 heterozygous knockout mice with cardiac ischemia model; conditional ERK2 knockout with T cell developmental analysis\",\n      \"pmids\": [\"15096454\", \"16226508\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for isoform-specific functions not resolved\", \"Whether dose-dependence (ERK2 higher expression) explains non-redundancy not excluded\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of TSC2 as an ERK substrate whose phosphorylation disrupts the TSC1–TSC2 complex and activates mTOR signaling placed ERK2 as a direct link between Ras-MAPK and PI3K-mTOR pathways, resolving cross-talk relevant to cell growth and tumorigenesis.\",\n      \"evidence\": \"In vitro phosphorylation, co-IP, mutagenesis, and in vivo xenograft rescue with non-phosphorylatable TSC2\",\n      \"pmids\": [\"15851026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of ERK vs. Akt-mediated TSC2 phosphorylation in different contexts unknown\", \"Whether ERK2 and ERK1 have differential activity toward TSC2 not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Characterization of PEA-15 binding through a reverse DEJL motif blocking ERK2 substrate access, and scaffold functions of IQGAP1, established that ERK2 signaling output is determined not only by phosphorylation state but by competitive binding partners that sequester or localize the kinase.\",\n      \"evidence\": \"Fluorescence anisotropy binding assay and peptide displacement (PEA-15); pull-down with purified proteins, siRNA knockdown and kinase assay (IQGAP1)\",\n      \"pmids\": [\"16324895\", \"14970219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full inventory of ERK2-sequestering proteins not available\", \"Structural basis of PEA-15–ERK2 complex not determined at atomic resolution at this time\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that ERK2 phosphorylates PKM2 at Ser37 to promote its nuclear translocation where PKM2 acts as β-catenin coactivator inducing c-Myc and the Warburg effect connected ERK2 directly to cancer metabolic reprogramming.\",\n      \"evidence\": \"In vitro kinase assay with docking site mutagenesis (Ile429/Leu431), nuclear fractionation, xenograft tumor model\",\n      \"pmids\": [\"23178880\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mechanism operates in all cancer types with activated ERK unknown\", \"Other kinases that might redundantly phosphorylate PKM2 Ser37 not excluded\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"NMR relaxation dispersion experiments revealed that dual phosphorylation triggers global two-state conformational exchange (kex ~300 s⁻¹) throughout the kinase core, providing the biophysical mechanism underlying the massive catalytic rate enhancement and explaining how a distal phosphorylation event remodels the active site.\",\n      \"evidence\": \"¹³C side-chain methyl NMR relaxation dispersion on phosphorylated and unphosphorylated ERK2\",\n      \"pmids\": [\"24550275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How substrate binding shifts the conformational equilibrium not determined\", \"Whether conformational dynamics differ for different substrate classes unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"A dimerization-disrupting small molecule showed that ERK2 dimerization specifically governs extranuclear (cytoplasmic) signaling and RAS-driven tumorigenesis without affecting nuclear ERK functions, resolving the long-standing question of what dimer-dependent signaling actually controls.\",\n      \"evidence\": \"Small molecule ERK dimerization inhibitor with dimerization assays, cancer cell transformation assays, and mouse tumor models\",\n      \"pmids\": [\"26267534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of dimer-specific extranuclear substrates not fully catalogued\", \"Whether monomer-selective inhibition spares normal tissue functions unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"An unbiased CRISPR screen in BRAF-inhibitor-resistant melanoma identified ERK2 as the kinase driving a phenotype switch (EMT-like, MITF shutdown) through JUNB/FRA1 upon drug withdrawal, establishing ERK2's role in therapy-induced adaptive plasticity.\",\n      \"evidence\": \"Genome-wide CRISPR-Cas9 knockout screen, transcriptomics, mouse tumor models, patient sample validation\",\n      \"pmids\": [\"28976960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERK1 can substitute for ERK2 in drug-addiction phenotype not fully resolved\", \"Direct ERK2 substrates mediating the MITF shutdown not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ERK2-mediated phosphorylation of ULK1 leading to its BTRC-dependent ubiquitination and proteasomal degradation linked ERK2 to suppression of mitophagy, accumulation of ROS-generating mitochondria, NLRP3 inflammasome activation, and breast cancer bone metastasis.\",\n      \"evidence\": \"In vitro kinase assay, ubiquitination assay, MEK inhibitor trametinib, xenograft bone metastasis model\",\n      \"pmids\": [\"33213267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mechanism is specific to breast cancer or generalizable unknown\", \"Relative contribution of ERK1 vs ERK2 to ULK1 phosphorylation not dissected\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ChIP-seq revealed ERK2 binds directly to gene promoters as a bidirectional transcription factor in gastric cancer cells, expanding its role beyond kinase to include direct DNA-binding transcriptional regulation.\",\n      \"evidence\": \"ChIP-seq, ChIP assay, RNA-seq, cell migration/invasion assays in gastric cancer cells\",\n      \"pmids\": [\"37817112\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"DNA-binding domain or motif within ERK2 not identified\", \"Whether this transcription factor function occurs in non-cancer contexts unknown\", \"Independent replication in other cell types needed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include the structural basis for isoform-specific (ERK2 vs ERK1) substrate selectivity, comprehensive identification of dimer-dependent versus monomer-dependent substrates, and the mechanism and physiological relevance of ERK2's direct DNA-binding transcription factor activity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural explanation for ERK2/ERK1 non-redundancy lacking\", \"Complete dimer-specific substrate catalog unavailable\", \"ERK2 DNA-binding mechanism unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 3, 5, 6, 7, 10, 11, 12, 15, 16, 17, 22, 26, 30, 37, 39, 40, 43, 47, 50]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 15, 26]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [15, 27]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [52]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [52]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9, 28, 44]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 9, 52]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [8, 52]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [34]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 6, 7, 13, 18, 21, 25, 44, 48]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [29, 35]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [23, 24, 46]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [34, 50]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [29, 35]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 10, 17, 37, 52]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 39, 46]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [41, 48]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [40, 50]}\n    ],\n    \"complexes\": [\n      \"Raf-MEK-ERK cascade module\",\n      \"β-arrestin/ERK2 signalosome\"\n    ],\n    \"partners\": [\n      \"MAP2K1\",\n      \"IQGAP1\",\n      \"PEA15\",\n      \"DUSP6\",\n      \"DUSP1\",\n      \"PTPN7\",\n      \"PARP1\",\n      \"GAB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}